| 時間：2020年08月05日 17:35:48 中財網 |
原標題:中國再生醫學:2020中期報告
CHARACTERISTICS OF GEM OF THE STOCK
EXCHANGE OF HONG KONG LIMITED (THE
「STOCK EXCHANGE」)
GEM has been positioned as a market designed to
accommodate small and mid-sized companies to
which a higher investment risk may be attached
than other companies listed on the Stock Exchange.
Prospective investors should be aware of the
potential risks of investing in such companies and
should make the decision to invest only after due
and careful consideration.
Given that the companies listed on GEM are
generally small and mid-sized companies, there is
a risk that securities traded on GEM may be more
susceptible to high market volatility than securities
traded on the Main Board and no assurance is given
that there will be a liquid market in the securities
traded on GEM.
Hong Kong Exchanges and Clearing Limited and the
Stock Exchange take no responsibility for the contents
of this report, make no representation as to its accuracy
or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in
reliance upon the whole or any part of the contents of this
report.
This report, for which the directors (the 「Directors」)
of China Regenerative Medicine International Limited
(the 「Company」) collectively and individually accept full
responsibility, includes particulars given in compliance
with the Rules Governing the Listing of Securities on
GEM of the Stock Exchange (the 「GEM Listing Rules」)
for the purpose of giving information with regard to the
Company. The Directors, having made all reasonable
enquiries, confirm that to the best of their knowledge and
belief the information contained in this report is accurate
and complete in all material respects and not misleading
or deceptive, and there are no other matters the omission
of which would make any statement herein or this report
misleading.
香港聯合交易所有限公司（「聯交
所」）
GEM之特點
GEM之定位乃為相比其他在聯交
所上市之公司帶有較高投資風險
之中小型公司提供一個上市之市
場。有意投資之人士應了解投資
於該等公司之潛在風險，並應經
過審慎周詳之考慮後方作出投資
決定。
由於GEM上市之公司普遍為中小
型公司，在GEM買賣之證券可能
會較在主板買賣之證券承受較大
之市場波動風險，同時無法保證
在GEM買賣之證券會有高流通量
之市場。
香港交易及結算所有限公司及聯
交所對本報告之內容概不負責，
對其準確性或完整性亦不發表任
何聲明，並明確表示概不就本報
告全部或任何部份內容而產生或
因依賴該等內容而引致之任何損
失承擔任何責任。
本報告旨在遵照聯交所GEM證券
上市規則（「GEM上市規則」）之規
定，提供有關中國再生醫學國際
有限公司（「本公司」）之資料。本
公司董事（「董事」）對此共同及個
別承擔全部責任。董事在作出一
切合理查詢後確認，就彼等所知
及所信，本報告所載資料在各重
要方面均屬準確完備，沒有誤導
或欺詐成分，且並無遺漏任何其
他事項，足以令致本報告或其所
載任何陳述產生誤導。
CONTENTS
目錄
Corporate Information公司資料
3
Condensed Consolidated Statement of 簡明綜合損益及6
Profit or Loss and Other Comprehensive Income其他全面收入表
Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表
8
Condensed Consolidated Statement of Changes in Equity簡明綜合權益變動表
10
Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表
13
Notes to the Condensed Consolidated Financial Statements簡明綜合財務報表附註
14
Management Discussion and Analysis管理層討論及分析
33
Other Information其他資料
41
In the event of any error or omission in the Chinese 本中期報告之中文翻譯如有任何
translation of this interim report, the English text shall 錯漏，應以英文為準。
prevail.
CORPORATE INFORMATION
公司資料
DIRECTORS
EXECUTIVE DIRECTORS
Mr. Wang Chuang (Chairman of the Board and
Chief Executive Officer)
Mr. Qiu Bin
NON-EXECUTIVE DIRECTORS
Mr. Wu Weiliang
Mr. Tsang Ho Yin
INDEPENDENT NON-EXECUTIVE
DIRECTORS
Dr. Fang Jun
Ms. Huo Chunyu
Ms. Yang Ying
COMPANY SECRETARY
Mr. Lee Pak Chung
NOMINATION COMMITTEE
Dr. Fang Jun (chairman of Nomination Committee)
Ms. Huo Chunyu
Ms. Yang Ying
REMUNERATION COMMITTEE
Dr. Fang Jun (chairman of Remuneration Committee)
Ms. Huo Chunyu
Ms. Yang Ying
AUDIT COMMITTEE
Ms. Yang Ying (chairman of Audit Committee)
Ms. Huo Chunyu
Dr. Fang Jun
董事
執行董事
王闖先生
（董事會主席及行政總裁）
邱斌先生
非執行董事
吳偉良先生
曾浩賢先生
獨立非執行董事
方俊博士
霍春玉女士
楊瀅女士
公司秘書
李柏聰先生
提名委員會
方俊博士（提名委員會主席）
霍春玉女士
楊瀅女士
薪酬委員會
方俊博士（薪酬委員會主席）
霍春玉女士
楊瀅女士
審核委員會
楊瀅女士（審核委員會主席）
霍春玉女士
方俊博士
REGISTERED OFFICE
P.O. Box 309
Ugland House
Grand Cayman
KY1-1104
Cayman Islands
HEAD OFFICE AND
PRINCIPAL PLACE OF BUSINESS
IN HONG KONG
Rooms 3006–10, 30/F
China Resources Building
Wanchai
Hong Kong
COMPLIANCE OFFICER
Mr. Qiu Bin
AUTHORIZED REPRESENTATIVES
Mr. Qiu Bin
Mr. Lee Pak Chung
PRINCIPAL BANKERS
Dah Sing Bank, Limited
36th Floor, Everbright Centre
108 Gloucester Road
Hong Kong
Hang Seng Bank Limited
83 Des Voeux Road Central
Hong Kong
AUDITOR
BDO Limited
25th Floor, Wing On Centre
111 Connaught Road Central
Hong Kong
註冊辦事處
P.O. Box 309
Ugland House
Grand Cayman
KY1-1104
Cayman Islands
總辦事處及香港
主要營業地點
香港
灣仔
華潤大廈
30樓3006–10室
監察主任
邱斌先生
授權代表
邱斌先生
李柏聰先生
主要往來銀行
大新銀行有限公司
香港
告士打道108號
光大中心36樓
恒生銀行有限公司
香港
德輔道中83號
核數師
香港立信德豪會計師事務所
有限公司
香港
幹諾道中111號
永安中心25樓
COMPLIANCE ADVISOR
Octal Capital Limited
801–805, 8/F, Nan Fung Tower
88 Connaught Road Central
Hong Kong
(appointed with effect from 12 August 2019)
LEGAL ADVISOR ON THE
CAYMAN ISLANDS LAW
Maples and Calder
53rd Floor, The Center
99 Queen’s Road Central
Hong Kong
CAYMAN ISLANDS PRINCIPAL
SHARE REGISTRAR AND
TRANSFER OFFICE
Maples Fund Services
(Cayman) Limited
P.O. Box 1093
Boundary Hall
Cricket Square
Grand Cayman
KY1-1102
Cayman Islands
HONG KONG BRANCH
SHARE REGISTRAR AND
TRANSFER OFFICE
Union Registrars Limited
Suites 3301–04, 33/F.
Two Chinachem Exchange Square,
338 King’s Road North Point
Hong Kong
COMPANY WEBSITE
www.crmi.hk
STOCK CODE
合規顧問
八方金融有限公司
香港
幹諾道中88號
南豐大廈8樓801–805室
（自二零一九年八月十二日起獲委任）
法律顧問
（開曼群島法律）
Maples and Calder
香港
皇后大道中99號
中環中心53樓
開曼群島股份
過戶登記總處
Maples and Calder
(Cayman) Limited
P.O. Box 1093
Boundary Hall
Cricket Square
Grand Cayman
KY1-1102
Cayman Islands
香港股份
過戶登記分處
聯合證券登記有限公司
香港
北角英皇道338號
華懋交易廣場2期
33樓3301–04室
公司網址
www.crmi.hk
股份代號
8158
The board of Directors (the 「Board」) of the Company 本公司董事會（「董事會」）謹此公
hereby announces the unaudited consolidated result 佈本公司及其附屬公司（統稱「本
of the Company and its subsidiaries (collectively, the 集團」）截至二零二零年六月三十
「Group」) for the three months and six months ended 日止三個月及六個月之未經審核
30 June 2020, together with the comparative unaudited 綜合業績，連同二零一九年同期
figures for the corresponding period in 2019 as follows:之未經審核比較數字如下：
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR
LOSS AND OTHER COMPREHENSIVE INCOME
簡明綜合損益及其他全面收入表
For the three months and six months ended 30 June 2020
截至二零二零年六月三十日止三個月及六個月
Three months ended Six months ended
30 June 30 June
截至六月三十日止三個月截至六月三十日止六個月
2020
二零二零年
2019
二零一九年
2020
二零二零年
2019
二零一九年
HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元
Notes
附註
Unaudited
未經審核
Unaudited
未經審核
Unaudited
未經審核
Unaudited
未經審核
Revenue收益
3 64,252 14,283 68,924 22,361
Cost of sales銷售成本
(13,904) (6,711) (15,595) (12,580)
Gross Profit毛利
50,348 7,572 53,329 9,781
Other income, gain and loss其他收入，收益及虧損
3 7,657 7,486 12,114 11,376
Selling and distribution expenses銷售及分銷開支
(46,911) (7,571) (49,148) (14,337)
Administrative and other expenses行政及其他開支
(169,626) (42,674) (186,996) (84,615)
Finance costs財務費用
5 (2,222) 347 (3,827) (2,230)
Loss before income tax除所得稅前虧損
6 (160,754) (34,840) (174,528) (80,025)
Income tax (expenses)/credit所得稅（開支）╱抵免
7 (3,226) 3,967 (3,226) 4,581
Loss for the period期內虧損
(163,980) (30,873) (177,754) (75,444)
Other comprehensive income其他全面收入
Items that may be reclassified 其後可能重新分類至
subsequently to profit or loss:損益之項目：
Exchange gain/(loss) on 換算海外業務財務
translation of financial 報表之匯兌
statements of foreign 收益╱（虧損）
operations5,358 (10,412) 6,183 (2,692)
Other comprehensive income
for the period
期內其他全面收入
5,358 (10,412) 6,183 (2,692)
Total comprehensive income
for the period
期內全面總收入
(158,622) (41,285) (171,571) (78,136)
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR
LOSS AND OTHER COMPREHENSIVE INCOME (Cont』d)
簡明綜合損益及其他全面收入表（續）
For the three months and six months ended 30 June 2020
截至二零二零年六月三十日止三個月及六個月
Three months ended
30 June
截至六月三十日止三個月
Six months ended
30 June
截至六月三十日止六個月
2020
二零二零年
2019
二零一九年
2020
二零二零年
2019
二零一九年
HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元
Notes
附註
Unaudited
未經審核
Unaudited
未經審核
Unaudited
未經審核
Unaudited
未經審核
Loss for the period
attributable to:
Owners of the CompanyNon-controlling interests
以下人士應佔期內
虧損：
本公司擁有人
非控股股東權益
(148,668)
(15,312)
(24,047)
(6,826)
(163,734)
(14,020)
(60,723)
(14,721)
(163,980) (30,873) (177,754) (75,444)
Total comprehensive loss for
the period attributable to:
Owners of the CompanyNon-controlling interests
以下人士應佔期內
全面總虧損：
本公司擁有人
非控股股東權益
(143,892)
(14,730)
(40,120)
(1,165)
(158,615)
(12,956)
(68,922)
(9,214)
(158,622) (41,285) (171,571) (78,136)
Loss per share– basic (HK cents)
– diluted (HK cents)
每股虧損 9
－基本（港仙）
－攤薄（港仙）
(12.132)
N/A 不適用
(2.735)
N/A 不適用
(15.559)
N/A 不適用
(6.906)
N/A不適用
8 China Regenerative Medicine International Limited . Interim Report 2020CONDENSED CONSOLIDATED STATEMENT OF
FINANCIAL POSITION
簡明綜合財務狀況表
As at 30 June 2020
於二零二零年六月三十日
30 June
2020
31 December
2019
二零二零年
六月三十日
二零一九年
十二月三十一日
HK$』000 HK$』000
千港元千港元
Notes Unaudited Audited
附註未經審核經審核
ASSETS AND LIABILITIES資產及負債
Non-current assets非流動資產
Property, plant and equipment物業、廠房及設備10 986 1,516
Right-of-use assets使用權資產– –
Other intangible assets其他無形資產11 12,195 16,345
Deposits for acquisition
of subsidiaries
收購附屬公司
之按金
100,000 146,512
Financial assets at fair value through
other comprehensive income
按公平值於其他全面收入
列賬之金融資產
31,522 31,522
Non-current rental deposits非流動租賃按金12 14,044 14,044
158,747 209,939
Current assets流動資產
Inventories存貨4,398 6,738
Trade receivables應收貿易賬項12 10,941 4,012
Deposits, prepayments and other
receivables
按金、預付款項及
其他應收賬項
12 286,221 14,514
Financial assets at fair value
through profit or loss
按公平值於損益列賬之
金融資產
– 299,520
Cash and bank balances現金及銀行結餘28,493 19,210
330,053 343,994
8 China Regenerative Medicine International Limited . Interim Report 2020CONDENSED CONSOLIDATED STATEMENT OF
FINANCIAL POSITION
簡明綜合財務狀況表
As at 30 June 2020
於二零二零年六月三十日
30 June
2020
31 December
2019
二零二零年
六月三十日
二零一九年
十二月三十一日
HK$』000 HK$』000
千港元千港元
Notes Unaudited Audited
附註未經審核經審核
ASSETS AND LIABILITIES資產及負債
Non-current assets非流動資產
Property, plant and equipment物業、廠房及設備10 986 1,516
Right-of-use assets使用權資產– –
Other intangible assets其他無形資產11 12,195 16,345
Deposits for acquisition
of subsidiaries
收購附屬公司
之按金
100,000 146,512
Financial assets at fair value through
other comprehensive income
按公平值於其他全面收入
列賬之金融資產
31,522 31,522
Non-current rental deposits非流動租賃按金12 14,044 14,044
158,747 209,939
Current assets流動資產
Inventories存貨4,398 6,738
Trade receivables應收貿易賬項12 10,941 4,012
Deposits, prepayments and other
receivables
按金、預付款項及
其他應收賬項
12 286,221 14,514
Financial assets at fair value
through profit or loss
按公平值於損益列賬之
金融資產
– 299,520
Cash and bank balances現金及銀行結餘28,493 19,210
330,053 343,994
9 2020 中期報告.中國再生醫學國際有限公司
30 June
2020
31 December
2019
二零二零年
六月三十日
二零一九年
十二月三十一日
HK$』000 HK$』000
千港元千港元
Notes Unaudited Audited
附註未經審核經審核
Current liabilities流動負債
Trade payables應付貿易賬項13 17,586 19,638
Accrued charges and other payables應計費用及其他應付賬項188,522 181,153
Contract liabilities合約負債8,754 21,169
Lease liabilities租賃負債22,677 24,094
Other borrowing其他借款14 70,642 55,172
Current tax liabilities當期稅項負債3,289 –
311,470 301,226
Net current assets流動資產淨值18,583 42,768
Total assets less current liabilities總資產減流動負債177,330 252,707
Non-current liabilities非流動負債
Shareholder loans股東貸款94,967 207,298
Convertible bonds可換股債券15 54,596 –
Lease liabilities租賃負債12,327 25,425
Deferred taxation遞延稅項1,626 2,351
163,516 235,074
NET ASSETS資產淨值13,814 17,633
CAPITAL AND RESERVES資金及儲備
Share capital股本16 315,858 175,858
Reserves儲備(213,895) (83,032)
Equity attributable to owners
of the Company
本公司擁有人應佔權益101,963 92,826
Non-controlling interests非控股股東權益(88,149) (75,193)
Total equity總權益13,814 17,633
CONDENSED CONSOLIDATED STATEMENT OF
FINANCIAL POSITION (Cont』d)
簡明綜合財務狀況表（續）
As at 30 June 2020
於二零二零年六月三十日
9 2020 中期報告.中國再生醫學國際有限公司
30 June
2020
31 December
2019
二零二零年
六月三十日
二零一九年
十二月三十一日
HK$』000 HK$』000
千港元千港元
Notes Unaudited Audited
附註未經審核經審核
Current liabilities流動負債
Trade payables應付貿易賬項13 17,586 19,638
Accrued charges and other payables應計費用及其他應付賬項188,522 181,153
Contract liabilities合約負債8,754 21,169
Lease liabilities租賃負債22,677 24,094
Other borrowing其他借款14 70,642 55,172
Current tax liabilities當期稅項負債3,289 –
311,470 301,226
Net current assets流動資產淨值18,583 42,768
Total assets less current liabilities總資產減流動負債177,330 252,707
Non-current liabilities非流動負債
Shareholder loans股東貸款94,967 207,298
Convertible bonds可換股債券15 54,596 –
Lease liabilities租賃負債12,327 25,425
Deferred taxation遞延稅項1,626 2,351
163,516 235,074
NET ASSETS資產淨值13,814 17,633
CAPITAL AND RESERVES資金及儲備
Share capital股本16 315,858 175,858
Reserves儲備(213,895) (83,032)
Equity attributable to owners
of the Company
本公司擁有人應佔權益101,963 92,826
Non-controlling interests非控股股東權益(88,149) (75,193)
Total equity總權益13,814 17,633
CONDENSED CONSOLIDATED STATEMENT OF
FINANCIAL POSITION (Cont』d)
簡明綜合財務狀況表（續）
As at 30 June 2020
於二零二零年六月三十日
CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN EQUITY
簡明綜合權益變動表
For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月
Noncontrolling
interestsAttributable to owners of the Company非控股Total
本公司擁有人應佔
股東權益
合計
Share
Share Share Translation Special Other option
capital premium reserve reserve reserve reserve
購股權
股本股份溢價換算儲備特殊儲備其他儲備儲備
HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元千港元千港元
Acc-
FVOCI umulated
reserve losses Sub-total
按公平值
於其他
全面收入
列賬之金融
資產儲備累計虧損小計
HK$』000 HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元千港元
At 1 January 2019 (audited)於二零一九年一月一日（經審核）
175,858 3,196,996 (32,995) (200) (410,463) 42,156 48,517 (2,414,090) 605,779 (38,516) 567,263
Loss for the period 期內虧損
– – – – – – – (60,723) (60,723) (14,721) (75,444)
Other comprehensive income其他全面收入
Exchange loss on translation 換算海外業務財務報表
of financial statements 之匯兌虧損
of foreign operations– – (8,199) – – – – – (8,199) 5,507 (2,692)
Total comprehensive 期內全面總收入
income for the period– – (8,199) – – – – (60,723) (68,922) (9,214) (78,136)
Equity-settled share-based payments以股權結算的以股份為基礎的付款
– – – – –3,281 – –3,281 –3,281
Lapse of share options購股權失效
– – – – –(3,686) –3,686 – – –
Changes in ownership interest in 控制權不變之附屬公司
subsidiaries without change in control所有權權益變動
– – – – (12,319) – – – (12,319) – (12,319)
At 30 June 2019 (unaudited)於二零一九年六月三十日
（未經審核）
175,858 3,196,996 (41,194) (200) (422,782) 41,751 48,517 (2,471,127) 527,819 (47,730) 480,089
CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN EQUITY (Cont』d)
簡明綜合權益變動表（續）
For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月
Noncontrolling
interestsAttributable to owners of the Company非控股Total
本公司擁有人應佔
股東權益
合計
Convertible
Share bonds Acc-
Share Share Translation Special Other option FVOCI equity umulated
capital premium reserve reserve reserve reserve reserve reserve losses Sub-total
按公平值
於其他
全面收入
購股權列賬之金融可換股債券
股本股份溢價換算儲備特殊儲備其他儲備儲備資產儲備權益儲備累計虧損小計
HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元
At 1 January 2020 於二零二零年一月一日
(audited)（經審核）
175,858 3,196,996 (23,749) (200) (413,100) 40,299 (81,406) – (2,801,872) 92,826 (75,193) 17,633
Loss for the period期內虧損
– – – – – – – – (163,734) (163,734) (14,020) (177,754)
Other comprehensive income其他全面收入
Exchange gain on translation 換算海外業務
of financial statements 財務報表
of foreign operations之匯兌收益
– – 5,119 – – – – – – 5,119 1,064 6,183
Total comprehensive
income for the period期內全面總收入
– – 5,119 – – – – – (163,734) (158,615) (12,956) (171,571)
Equity-settled share-based 以股權結算的以股份為
payments基礎的付款
– – – – – 1,425 – – – 1,425 – 1,425
Lapse of share options購股權失效
– – – – – (2,860) – – 2,860 – – –
Share placement股份配售
100,000 – – – – – – – – 100,000 – 100,000
Share issue expenses股份發行開支
– (817) – – – – – – – (817) – (817)
Recognition of equity component of 確認可換股債券權益部分
convertible bonds– – – – – – – 40,246 – 40,246 – 40,246
Conversion of convertible bonds 轉換可換股債券
40,000 313 – – – – – (13,415) – 26,898 – 26,898
At 30 June 2020 (unaudited)於二零二零年六月三十日
（未經審核）
315,858 3,196,492 (18,630) (200) (413,100) 38,864 (81,406) 26,831 (2,962,746) 101,963 (88,149) 13,814
CONDENSED CONSOLIDATED STATEMENT OF
CHANGES IN EQUITY (Cont』d)
簡明綜合權益變動表（續）
For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月
The special reserve represents the difference between
the nominal value of the shares of the acquired
subsidiaries and the nominal value of the Company’s
shares issued for their acquisition at the time of the
Group’s reorganisation in 2001.
The other reserve represents (i) the difference between
the fair value of consideration paid to increase the
shareholding in subsidiaries and the amount of
adjustment to non-controlling interest; and (ii) deemed
capital contribution from shareholders, represented
the difference between the principal amount of the
shareholder’s loan and its fair value. The fair value is
determined by discounting the estimate future cash flows
throughout the expected life of the repayment.
特殊儲備指本集團於二零零一年
重組時，被收購附屬公司股份面
值與本公司就收購該等附屬公司
而予以發行之本公司股份面值之
差額。
其他儲備指
(i)就增加於附屬公司
之股權所付代價之公平值與非控
股股東權益調整金額之差額及(ii)
視作股東注資指股東貸款本金額
與其公平值之間的差額。公平值
按整個預期償還期間貼現估計未
來現金流釐定。
13 2020 中期報告.中國再生醫學國際有限公司
CONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS
簡明綜合現金流量表
For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月
Six months ended 30 June
截至六月三十日止六個月
2020 2019
二零二零年二零一九年
HK$』000 HK$』000
千港元千港元
Unaudited Unaudited
未經審核未經審核
Net cash (used in)/generated from
operating activities
經營活動（耗用）╱所得
現金淨額(285,261) 9,959
Net cash generated from
investing activities
投資活動所得
現金淨額23,587 426,183
Net cash generated from/(used in)
financing activities
融資活動所得╱（耗用）
現金淨額264,448 (428,386)
Net increase in cash
and cash equivalents
現金及現金等值項目之
增加淨額2,774 7,756
Effect of exchange rate changes
on cash and cash equivalents
匯率變動對現金及現金等值項目
之影響6,509 (7,386)
Cash and cash equivalents at
beginning of the period
期初之現金及現金等值項目
19,210 20,062
Cash and cash equivalents at
end of the period
期末之現金及現金等值項目
28,493 20,432
13 2020 中期報告.中國再生醫學國際有限公司
CONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS
簡明綜合現金流量表
For the six months ended 30 June 2020
截至二零二零年六月三十日止六個月
Six months ended 30 June
截至六月三十日止六個月
2020 2019
二零二零年二零一九年
HK$』000 HK$』000
千港元千港元
Unaudited Unaudited
未經審核未經審核
Net cash (used in)/generated from
operating activities
經營活動（耗用）╱所得
現金淨額(285,261) 9,959
Net cash generated from
investing activities
投資活動所得
現金淨額23,587 426,183
Net cash generated from/(used in)
financing activities
融資活動所得╱（耗用）
現金淨額264,448 (428,386)
Net increase in cash
and cash equivalents
現金及現金等值項目之
增加淨額2,774 7,756
Effect of exchange rate changes
on cash and cash equivalents
匯率變動對現金及現金等值項目
之影響6,509 (7,386)
Cash and cash equivalents at
beginning of the period
期初之現金及現金等值項目
19,210 20,062
Cash and cash equivalents at
end of the period
期末之現金及現金等值項目
28,493 20,432
NOTES TO THE CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS
簡明綜合財務報表附註
1. GENERAL INFORMATION 1. 一般資料
China Regenerative Medicine International Limited (the 中國再生醫學國際有限公司
「Company」) was incorporated as an exempted company （「本公司」）於二零零一年四月
with limited liability in the Cayman Islands under the 二十日根據開曼群島公司法
Companies Law (Revision 2001) of Cayman Islands on （二零零一年修訂版）在開曼
20 April 2001. The address of its registered office is 群島註冊成立為獲豁免有限公
P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, 司。其註冊辦事處及主要營
Cayman Islands and its principal place of business is 業地點之地址分別為P.O. Box
Rooms 3006-10, 30/F., China Resources Building, 309, Ugland House, Grand
26 Harbour Road, Wanchai, Hong Kong. Cayman, KY1-1104, Cayman
Islands及香港灣仔港灣道26號
華潤大廈30樓3006–10室。
The Company’s shares are listed on GEM of The Stock 本公司股份於香港聯合交易
Exchange of Hong Kong Limited (the 「Stock Exchange」). 所有限公司（「聯交所」）GEMThe Company is an investment holding company. The 上市。本公司為一間投資控股
principal activities of its subsidiaries are research and 公司。其附屬公司的主要業務
development of bio-medical products; production and 為研發生物醫學產品；生產及
sale of tissue engineering and stem cell products; sale 銷售組織工程產品及幹細胞產
and distribution of cosmetic and other products; sale 品；銷售及分銷化妝品及其他
and distribution of medical equipment; and provision of 產品；銷售及分銷醫療設備及
healthcare services. 提供保健服務。
2. BASIS OF PREPARATION 2. 編製基準
The unaudited condensed consolidated interim financial 截至二零二零年六月三十日止
statements for the six months ended 30 June 2020 六個月之未經審核簡明綜合中
have been prepared in accordance with the Hong Kong 期財務報表乃遵照香港會計師
Financial Reporting Standards (「HKFRSs」, which also 公會（「香港會計師公會」）頒佈
include the Hong Kong Accounting Standard (「HKAS」) 之香港財務報告準則（「香港財
and Interpretations) issued by the Hong Kong Institute 務報告準則」，亦包括香港會
of Certified Public Accountants (「HKICPA」), and with 計準則（「香港會計準則」）及詮
applicable disclosure requirements of the GEM Listing 釋），以及GEM上市規則及香
Rules and the Hong Kong Companies Ordinance. 港公司條例之適用披露規定而
編製。
2. BASIS OF PREPARATION (Cont』d) 2. 編製基準（續）
The unaudited condensed consolidated financial
statements do not include all the information and
disclosures required in the annual financial statements
and should be read in conjunction with the audited annual
results of the Group for the year ended 31 December
2019, released on 30 June 2020. The accounting policies
and basis of preparation adopted in the preparation of the
unaudited condensed consolidated financial statements
are the same as those used in the Group’s audited annual
results for the year ended 31 December 2019, released on
30 June 2020.
The unaudited condensed consolidated interim financial
statements for the six months ended 30 June 2020 have
been prepared on the historical cost basis except for
certain financial instruments, which are stated at fair value.
It should be noted that accounting estimates and
assumptions are used in preparation of the unaudited
condensed consolidated financial statements. Although
these estimates are based on management’s best
knowledge and judgement of current events and actions,
actual results may ultimately differ from those estimates.
The Group had incurred a loss for the period
attributable to owners of the Company of approximately
HK$163,734,000 for the six months ended 30 June 2020
and based upon the unaudited condensed consolidated
statement of financial position of the Group as at 30
June 2020, the Group has a net assets of approximately
HK$13.8 million as at 30 June 2020. This situation
indicates the existence of a material uncertainty that may
cast significant doubt on the Group’s ability to continue
as a going concern and therefore, the Group may not be
able to realise its assets and discharge its liabilities in the
normal course of business.
未經審核簡明綜合財務報表並
無載有年度財務報表所規定的
所有資料及披露事項，應與二
零二零年六月三十日刊發之本
集團截至二零一九年十二月三
十一日止年度之經審核年度業
績一併閱讀。編製未經審核簡
明綜合財務報表所採納之會計
政策及編製基準與二零二零年
六月三十日刊發之本集團截至
二零一九年十二月三十一日止
年度之經審核年度業績所採納
者一致。
截至二零二零年六月三十日止
六個月之未經審核簡明綜合中
期財務報表乃按歷史成本基準
編製，惟若干金融工具則以公
平值列賬。
務請註意，編製未經審核簡明
綜合財務報表時會採用會計估
計及假設。儘管此等估計乃基
於管理層對現時事件及行動之
最深切了解及判斷而作出，惟
實際結果最終或會有別於估計
之情況。
截至二零二零年六月三十日
止六個月，本集團產生本
公司擁有人應佔期內虧損約
163,734,000港元，而基於本
集團於二零二零年六月三十日
之未經審核簡明綜合財務狀
況表，本集團於二零二零年
六月三十日的資產淨值約為
13,800,000港元。此種情況表
明存在可能會對本集團的持續
經營能力產生重大懷疑的重大
不確定性，因此，本集團可能
無法在正常業務過程中變現其
資產並清償其負債。
2.
BASIS OF PREPARATION (Cont』d) 2. 編製基準（續）
Management plans to improve the Group’s liquidity by:
(i)
The disposal of its financial assets at fair value
through profit or loss with the carrying amount
of HK$267.8 million as at 31 December 2019 to
Mr. Xiong Qiangen (「Mr. Xiong」), an independent
third party. On 6 January 2020, the Group
disposed 15% of this investment to Mr. Xiong at
the consideration of US$5.8 million (equivalent
to HK$45.1 million). Details are set out in the
Company’s announcement dated 6 January 2020
and 20 January 2020. Mr. Xiong is obligated to
settle the consideration in full by 30 June 2020,
but he has the option to pay by installments
on a schedule to be agreed with the Group.
Upon payment of the first installment of the
consideration, Mr. Xiong will acquire legal title to
15% of this investment. On 21 February 2020, the
Group entered into agreement with Mr. Xiong to
dispose the remaining 85% of this investment at
the consideration of US$32.9 million (equivalent
to HK$256.6 million). Details are set out in the
Company’s announcement dated 21 February
2020 and the circular dated 20 April 2020. Mr.
Xiong shall pay US$3.9 million (equivalent to
HK$30.4 million) for settlement of the deposit. The
settlement can be made by (i) offsetting against
the amounts due by the Group to Mr. Xiong; or (ii)
by cash. Mr. Xiong shall pay the remaining US$9
million (equivalent to HK$70.2 million), US$10
million (equivalent to HK$78.0 million) and US$10
million (equivalent to HK$78.0 million) by 30 June
2020, 30 September 2020 and 30 December
2020 respectively. This transaction has been
approved by the shareholders of the Company
pursuant to an ordinary resolution passed at an
extraordinary general meeting held on 7 May
2020. All amounts due from Mr. Xiong up to 30
June 2020 have been properly settled. As at 30
June 2020, the amount due to Mr. Xiong by the
Group amounted to HK$70.6 million, the Directors
maintain close communication with Mr. Xiong
and believe that Mr. Xiong will settle the sum of
US$10 million by 30 September 2020 and US$10
million by 31 December 2020 by ways of offsetting
against the amounts due by the Group to Mr.
Xiong and by cash.
管理層計劃通過以下事項改善
本集團之流動資金狀況：
(i)
向一名獨立第三方熊千根先
生（「熊先生」）出售其於二
零一九年十二月三十一日賬
面值為267,800,000港元之
按公平值於損益列賬之金
融資產。於二零二零年一
月六日，本集團向熊先生出
售其於此項投資的15%，
代價為5,800,000美元（相當
於45,100,000港元）。詳情
載於本公司日期為二零二
零年一月六日及二零二零年
一月二十日的公告。熊先生
須於二零二零年六月三十日
前結清代價，惟彼可選擇按
與本集團協定的時間表分
期付款。於支付代價首期
款後，熊先生將獲得此項
投資15%的法定所有權。
於二零二零年二月二十一
日，本集團與熊先生訂立協
議，以出售此項投資之餘下
85%，代價為
32,900,000
美元（相當於256,600,000
港元）。詳情載於本公司日
期為二零二零年二月二十一
日的公告及日期為二零二零
年四月二十日的通函。熊
先生將支付3,900,000美元
（相當於
30,400,000港元）
以結付按金。該按金可按
以下方式結付：
(i)抵銷本集
團結欠熊先生的款項；或
(ii)
以現金支付。熊先生將分
別於二零二零年六月三十
日、二零二零年九月三十
日及二零二零年十二月三
十日前支付餘下9,000,000
美元（相當於70,200,000港
元）、
10,000,000美元（相
當於
78,000,000港元）及
10,000,000美元（相當於
78,000,000港元）。是項交
易已由本公司股東根據於二
零二零年五月七日舉行的股
東特別大會通過的普通決議
案批准。直至二零二零年六
月三十日止應收熊先生的全
部款項已妥為結付。於二零
二零年六月三十日，應付熊
先生款項為70,600,000港
元，董事與熊先生維持緊密
溝通，並相信熊先生將於二
零二零九月三十日及二零二
零年十二月三十一日前分別
結付金額10,000,000美元及
10,000,000美元，以抵銷本
集團結欠熊先生的款項及現
金為方式。
2. BASIS OF PREPARATION (Cont』d) 2. 編製基準（續）
(ii) Issue of new shares and convertible bonds of (ii) 本公司發行新股及可換
the Company. On 2 March 2020, the Company 股債券。於二零二零年
entered into (i) the placing agreement with joint 三月二日，本公司(i)與
placing agents to procure not less than six 聯席配售代理訂立配售
placees to subscribe for up to 500 million ordinary 協議以促使不少於六名
shares of the Company at the placing price of 承配人以每股股份0.20HK$0.20 per share; and (ii) the subscription and 港元之配售價認購最多
settlement agreement with All Favour to subscribe 500,000,000股本公司
for a 3-year zero coupon rate convertible bonds 普通股；及
(ii)與全輝訂
(「Convertible Bonds」) in the principal amount of 立認購及清償協議，以
HK$120 million at its face value and All Favour 按面值認購本金額為
shall pay the subscription price upon completion 120,000,000港元之三
by setting off against the shareholder’s loan in 年期零息率可換股債券
the amount of HK$120 million. Details are set out （可換股債券」），且全
in the Company’s announcement dated 2 March 輝於完成時透過抵銷金
2020 and the circular dated 27 March 2020. 額為
120,000,000港元
The subscription and settlement agreement was 之股東貸款支付認購
completed on 21 April 2020 with the issuance of 價。詳情載於本公司日
the Convertible Bonds. The Convertible Bonds 期為二零二零年三月二
were fully converted into a total of 600,000,000 日的公告及二零二零年
ordinary share of the Company before the date 三月二十七日的通函。
of this interim report and accordingly the liability 認購及清償協議於二零
arising from the Convertible Bonds has been fully 二零年四月二十一日隨
discharged. The placing of new ordinary shares 著發行可換股債券而完
was completed on 15 May 2020. 成。可換股債券於本中
期報告日期前悉數轉換
為合共
600,000,000股
本公司普通股，而據此
可換股債券產生的負債
已悉數清償。新普通股
的配售於二零二零年五
月十五日完成。
(iii) In April 2020, All Favour has made available to (iii) 於二零二零年四月，全
the Group an interest-free term loan facility of up 輝已向本集團提供免
to HK$100 million repayable in full on or before 息定期貸款融資最多
30 September 2021. In June 2020, the Company 100,000,000港元，須
agreed with All Favour to cancel the loan facility 於二零二一年九月三十
and is negotiating with the beneficial controlling 日或之前悉數償還。於
party of All Favour to provide financing of not less 二零二零年六月，本公
than HK$60 million. The beneficial controlling party 司與全輝同意取消貸款
of All Favour also confirmed his intention to provide 融資，並與全輝的實益
sufficient financial resources to the Company when 控制方磋商，提供不少
so required by the Company. 於60,000,000港元的融
資。全輝的實益控制方
亦確認其應本公司要求
向本公司提供足夠財務
資源的意向。
2.
BASIS OF PREPARATION (Cont』d) 2. 編製基準（續）
(iv)
The Company has made its best effort to improve
the Group’s operational performance and to
extend the Group’s sale network in the PRC,
especially in the healthcare products and services
segment and as a result, the performance of the
healthcare products and services segment in the
second quarter of 2020 has substantially improved
and generated operating profit and improved the
liquidity of the Group. The extended sale network
is expected to improve the profitability of the
business of the Group for the years coming. The
Group will continue to make effort to implement
measures to improve the Group’s operational
performance and financial position. The Board will
continuously evaluate the business environment,
the existing business portfolio and income streams
of the Group and improve the profitability of the
Group.
(v)
The Company will continue to implement
measures aiming at improving the working capital
and cash flows of the Group, including close
monitoring of general administrative expenses
and operating costs and soliciting more potential
customers. The Company may also consider
disposing of non-profit making businesses and
to review its plan of acquisition in order to reduce
operating costs and improve working capital.
In June 2020, the Group cancelled a proposed
acquisition, and the deposit of HK$46,512,000
has been and will be returned to the Group by
stages with last portion thereof be returned by
December 2020.
(vi)
The Company will also consider alternative means
of fund raising which may or may not involve
issuance of shares or convertible bonds of the
Company and/or the realization of assets, financial
assets or otherwise.
Accordingly, the unaudited consolidated condensed
financial statements have been prepared on a going
concern basis.
(iv) 本公司已竭盡所能改善本
集團的經營業績及擴大本
集團的中國銷售網絡，尤
其是在大健康產品及服務
分部，因此，於二零二零
年第二季度，大健康產品
及服務分部的業績顯著改
善，並產生經營溢利，改
善本集團的流動性。經擴
大的銷售網絡預期將於未
來數年可提高本集團業務
的盈利能力。本集團將繼
續致力實施改善本集團的
經營業績及財務狀況的措
施。董事會將持續評估本
集團的營商環境、現有業
務組合及收入來源，並提
高本集團的盈利能力。
(v)
本公司將繼續採取旨在改
善本集團營運資金及現
金流量的措施，包括嚴密
監控一般行政開支及營運
成本，並招攬更多潛在客
戶。本公司亦可能考慮出
售非營利性業務，並檢討
其收購計劃，以降低營運
成本及改善營運資金。於
二零二零年六月，本集團
取消一項建議收購事項，
並已經及將會分期向本集
團退還按金46,512,000港
元，最後一期將於二零二
零年十二月退還。
(vi) 本公司亦將考慮可能涉及
或不涉及發行本公司股份
或可轉換債券的其他集資
方式及╱或變現資產、金
融資產或其他的融資方式。
因此，未經審核簡明綜合財務
報表已按持續經營基準編製。
3. REVENUE AND OTHER INCOME 3. 收益及其他收入
The Group’s turnover represents revenue from its principal
activities, measured at the net invoiced value of goods
sold, after allowances for returns and trade discounts
during the periods presented.
本集團之營業額指於該等所示
期間內來自其主要活動，按扣
除退貨撥備及貿易折扣後之已
售貨品發票淨值計算之收益。
Other income recognised during the period is as follows: 期內已確認之其他收入如下：
Six months ended 30 June
截至六月三十日止六個月
2020
二零二零年
HK$』000
千港元
38
394
2,340
6,154
2,398
790
12,114
二零一九年
HK$』000
千港元
3,620
Gain on deregistration of 取消註冊附屬公司之
subsidiaries收益
Bank interest income 銀行利息收入
–
Gain on disposal of financial assets 出售按公平值於損益列
at fair value through profit or loss賬之金融資產之收益
–
Gain on modification of leases修改租賃之收益
–
Government grant income (note)政府補貼收入（附註）
6,554
Others 其他
1,202
11,376
Note: These government grants were received and 附註：本集團已收取該等政府
had complied with all attached conditions and 補貼並符合所有附加條
therefore were recognised in profit or loss during 件，因此該等政府補貼
the period. 於期內在損益中確認。
4.
SEGMENT INFORMATION 4. 分部資料
The Group has identified the following reportable 本集團已確認以下須予呈報分
segments: 部：
(i)
Dermatology and others – production and sale of (i) 皮膚及其他－皮膚產品及
dermatology products and services and trading of 服務的生產及銷售和買賣
medical equipment; 醫療設備；
(ii)
Cosmetic products and others – production and (ii) 化妝品及其他－化妝產品
sale of cosmetic products and services; 及服務的生產及銷售；
(iii)
Cell products and services – production and sale (iii) 細胞產品及服務－細胞產
of cell products and services; 品和服務的生產和銷售；
(iv)
Healthcare products and services – production (iv) 大健康產品及服務－大健
and sale of healthcare products and services;
康產品和服務的生產和銷
售；
(v)
Ophthalmology products – production and sale of (v) 眼科產品－眼科產品的生
ophthalmology products; and 產及銷售；及
(vi)
Stomatology products and others – production (vi) 口腔產品及其他－口腔產
and sale of stomatology products and others. 品及其他的生產及銷售。
The operating segments are monitored and strategic 根據經調整分部經營業績就該
decisions are made on the basis of adjusted segment 等經營分部實施監控及作出戰
operating results. 略決策。
4. SEGMENT INFORMATION (Cont』d) 4. 分部資料（續）
The totals presented for the Group’s operating segments
reconcile to the Group’s key financial figures as presented
in the condensed consolidated financial statements are as
follows:
本集團經營分部列示的總額與
本集團於簡明綜合財務報表列
示的關鍵財務數據對賬如下：
Dermatology and Cell products and Ophthalmology Stomatology products Cosmetic products and Healthcare
others services products and others services products and services Total
皮膚及其他細胞產品及服務眼科產品口腔科產品及其他化妝品及服務大健康產品及服務合計
2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019 2020 2019
二零二零年二零一九年二零二零年二零一九年二零二零年二零一九年二零二零年二零一九年二零二零年二零一九年二零二零年二零一九年二零二零年二零一九年
HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元千港元
Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited Unaudited
未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核未經審核
THREE MONTHS 截至六月三十日
ENDED 30 JUNE止三個月
Reportable segment revenue須予呈報分部收益
– 622 1,778 1,249 383 654 8,092 5,210 5,487 4,311 48,511 2,587 64,251 14,633
Reportable segment profit/(loss)須予呈報分部溢利╱
（虧損）
(54,297) (10,461) (25,057) (1,136) (24,177) 3,192 (38,482) (1,864) (24,852) (3,642) 15,253 (2,000) (151,612) (15,911)
Amortisation of other intangible assets其他無形資產攤銷
– 5,174 – 954 – – (207) 1,482 – – – – (207) 7,610
Depreciation折舊
123 (577) (696) 2,152 – 1,244 3 69 – 119 – (698) (570) 2,309
Interest income利息收入
2 1 1 2 7 1 2 – – (1) – – 12 3
SIX MONTHS ENDED 30 JUNE截至六月三十日
止六個月
Reportable segment revenue須予呈報分部收益
– 736 3,132 2,589 860 1,509 8,626 8,498 6,999 6,782 49,307 2,597 68,924 22,711
Reportable segment profit/(loss)須予呈報分部溢利╱
（虧損）
(57,679) (18,188) (26,417) (12,557) (24,528) (2,376) (39,915) (3,242) (20,498) (7,446) 14,675 (5,907) (154,362) (49,716)
Amortisation of other intangible assets其他無形資產攤銷
– 8,015 – 954 – – 462 3,052 – – – – 462 12,021
Depreciation折舊
246 1,092 122 3,403 – 1,508 5 164 – 276 – – 373 6,443
Interest income利息收入
3 2 1 2 14 2 3 1 – (1) – – 21 6
AT 30 JUNE於六月三十日
Reportable segment assets須予呈報分部資產
63,537 234,609 31,845 76,182 47,317 38,516 38,825 156,211 29,526 41,524 21,346 41,436 232,396 588,478
Additions to non-current segment assets 期內非流動分部資產之
during the period添置
– – – – – 3 – 15 – – – – – 18
Reportable segment liabilities須予呈報分部負債
(4,042) 49,949 104,295 57.752 18,393 29,706 10,000 4,480 58,655 48,867 30,522 28,312 221,865 219,066
5. FINANCE COSTS 5. 財務費用
Six months ended 30 June
截至六月三十日止六個月
2020
二零二零年
HK$』000
千港元
Unaudited
未經審核
2019
二零一九年
HK$』000
千港元
Unaudited
未經審核
Interest on bank borrowings 銀行借款及其他應付
and other payables賬項之利息
1,464
Interest on lease liabilities 租賃負債之利息
766
Interest on liability component of 按攤銷成本計量的
convertible bonds measured at 可換股債券負債部分
amortised cost之利息
–
1,083
1,004
1,740
3,827
2,230
6. LOSS BEFORE INCOME TAX
6. 除所得稅前虧損
Six months ended 30 June
截至六月三十日止六個月
2020
二零二零年
HK$』000
千港元
Unaudited
未經審核
462
64,736
564
–
1,425
190
19,617
1,292
77,706
759
6,439
二零一九年
HK$』000
千港元
Unaudited
未經審核
Loss before income tax has been 除所得稅前虧損已扣
arrived at after charging/(crediting):除╱（計入）下列各項：
Amortisation of other intangible 其他無形資產攤銷
assets, included in （已包括在行政
administrative expenses開支中）
12,021
Advertising and marketing廣告及市場推廣
4,173
Depreciation for property, plant and 物業、廠房及設備折舊
equipment
6,972
Depreciation for right-of-use assets 使用權資產折舊
6,570
Equity-settled share-based 以股權結算的以股份
payments為基礎的付款
3,281
Exchange difference, net 匯兌差額（淨額）
(515)
Short term lease and low value
短期租賃及低價值
lease expenses租賃開支
6,861
Research and development 研發成本（附註(i)）
costs (note (i))
7,193
Employee benefit expenses 僱員福利開支
(including directors』 emoluments):（包括董事酬金）：
Salaries, wages and 薪金、工資及
other benefits
其他福利
35,052
Share-based payments 以股份為基礎的付款
2,039
Retirement benefit schemed 退休福利計劃供款
contributions
3,427
(i) Research and development costs included (i) 研發成本包括研發部其他
amortisation of other intangible assets, 無形資產攤銷、折舊及僱
depreciation and staff costs for employees in 員的員工成本，亦已計入
Research and Development Department, which 上表單獨披露的金額內。
are also included in the amount disclosed
separately above.
7. INCOME TAX (EXPENSES)/CREDIT 7. 所得稅（開支）╱抵免
Six months ended 30 June
截至六月三十日止六個月
2020
二零二零年
HK$』000
千港元
Unaudited
未經審核
–
(3,316)
–
90
(3,226)
二零一九年
HK$』000
千港元
Unaudited
未經審核
Income tax – for the current period 所得稅－本期內
Hong Kong 香港
–
The PRC 中國
–
Overprovision in respect of prior years過往年度超額撥備
2,899
Deferred taxation 遞延稅項
1,682
4,581
Total income tax (expenses)/credit 總所得稅（開支）╱抵免
For the six months ended 30 June 2020 and 2019, no
Hong Kong profits tax had been provided in the unaudited
consolidated interim financial statements as the Group
had no assessable profits.
截至二零二零年及二零一九年
六月三十日止六個月，由於本
集團並無應課稅溢利，故並無
於未經審核綜合中期財務報表
中作出香港利得稅撥備。
PRC income tax has been provided at the applicable PRC
enterprise income tax rate of 25%.
中國所得稅乃按適用中國企業
所得稅稅率25%撥備。
Taxation on overseas profits has been calculated on the
estimated assessable profits for the period at the rates
of taxation prevailing in the countries in which the Group
operates.
有關海外溢利之稅項乃根據期
內估計應課稅溢利，按本集團
經營所在國家之現行稅率計算。
8. DIVIDENDS 8. 股息
The Board does not recommend the payment of interim
dividend for the six months ended 30 June 2020 (2019:
Nil).
董事會並不建議派付截至二零
二零年六月三十日止六個月之
中期股息（二零一九年：無）。
24 China Regenerative Medicine International Limited . Interim Report 20209. LOSS PER SHARE
The calculation of the basic and diluted loss per share
attributable to owners of the Company is based on the
following data:
Three months ended 30 June Six months ended 30 June
截至六月三十日止三個月截至六月三十日止六個月
2020 2019 2020 2019
二零二零年二零一九年二零二零年二零一九年
HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元
Unaudited Unaudited Unaudited Unaudited
未經審核未經審核未經審核未經審核
Loss for the period attributable to
owners of the Company for the
purpose of basic loss per share
用以計算每股基本虧損之
本公司擁有人應佔期內
虧損(148,668) (24,047) (163,734) (60,723)
2020 2019 2020 2019
Number of shares股份數目二零二零年二零一九年二零二零年二零一九年
Weighted average number of
ordinary shares for the purpose
of basic loss per share
用以計算每股基本虧損之
普通股加權平均數
1,225,443,346 879,289,500 1,052,366,423 879,289,500
For the three months and six months ended 30 June 2020
and 2019, diluted losses per share attributable to owners
of the Company were not presented because the impact
of the exercise of share options and convertible bonds
was anti-dilutive.
9. 每股虧損
本公司擁有人應佔每股基本及
攤薄虧損乃根據以下數據計算：
截至二零二零年及二零一九
年六月三十日止三個月及六個
月，由於行使購股權及可換股
債券具反攤薄影響，故並無呈
列本公司擁有人應佔每股攤薄
虧損。
24 China Regenerative Medicine International Limited . Interim Report 20209. LOSS PER SHARE
The calculation of the basic and diluted loss per share
attributable to owners of the Company is based on the
following data:
Three months ended 30 June Six months ended 30 June
截至六月三十日止三個月截至六月三十日止六個月
2020 2019 2020 2019
二零二零年二零一九年二零二零年二零一九年
HK$』000 HK$』000 HK$』000 HK$』000
千港元千港元千港元千港元
Unaudited Unaudited Unaudited Unaudited
未經審核未經審核未經審核未經審核
Loss for the period attributable to
owners of the Company for the
purpose of basic loss per share
用以計算每股基本虧損之
本公司擁有人應佔期內
虧損(148,668) (24,047) (163,734) (60,723)
2020 2019 2020 2019
Number of shares股份數目二零二零年二零一九年二零二零年二零一九年
Weighted average number of
ordinary shares for the purpose
of basic loss per share
用以計算每股基本虧損之
普通股加權平均數
1,225,443,346 879,289,500 1,052,366,423 879,289,500
For the three months and six months ended 30 June 2020
and 2019, diluted losses per share attributable to owners
of the Company were not presented because the impact
of the exercise of share options and convertible bonds
was anti-dilutive.
9. 每股虧損
本公司擁有人應佔每股基本及
攤薄虧損乃根據以下數據計算：
截至二零二零年及二零一九
年六月三十日止三個月及六個
月，由於行使購股權及可換股
債券具反攤薄影響，故並無呈
列本公司擁有人應佔每股攤薄
虧損。
10. PROPERTY, PLANT AND EQUIPMENT 10. 物業、廠房及設備
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
1,516
33
–
–
1
(564)
–
986
31 December
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
Net book value, beginning of 期初╱年初賬面淨值
period/year
105,245
Exchange differences匯兌差額
(1,788)
Disposals出售
(1,079)
Disposal of a subsidiary出售一間附屬公司
(242)
Additions添置
2,190
Depreciation折舊
(8,692)
Impairment loss減值虧損
(94,118)
1,516Net book value, end of period/year期╱年末賬面淨值
11. OTHER INTANGIBLE ASSETS 11. 其他無形資產
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
16,345
537
(4,225)
(462)
–
12,195
31 December
2019
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
Net book value, beginning of 期初╱年初賬面淨值
period/year
111,844
Additions添置
3,549
Exchange differences匯兌差額
(5,506)
Amortisation攤銷
(22,845)
Impairment loss減值虧損
(70,697)
16,345
Net book value, end of period/year期╱年末賬面淨值
12. TRADE RECEIVABLES, DEPOSITS, 12. 應收貿易賬項、按金、預付
PREPAYMENTS AND OTHER RECEIVABLES 款項及其他應收賬項
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
10,941
14,044
3,942
40,205
73
242,001
300,265
31 December
2019
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
4,012
Trade receivables應收貿易賬項
14,044
Other deposits其他按金
Rental deposit租賃按金
3,946
Prepayments預付款項
7,274
Bank interest receivables應收銀行利息
73
Other receivables其他應收賬項
3,221
28,558
As at 30 June 2020, aging analysis of trade receivables 於二零二零年六月三十日，應
(net of impairment losses) based on sale invoice date and 收貿易賬項（扣除減值虧損）按
net of provision, is as follows: 銷售發票日期及扣除撥備後之
賬齡分析如下：
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
7,724
3,217
10,941
31 December
2019
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
2,353
Over 90 days but less than 1 year超過90天但少於1年
0–90 days 0–90天
1,659
4,012
The Group allows an average credit period of 60–180 days 本集團給予其客戶之平均信貸
to its customers.期為60至180天。
13. TRADE PAYABLES 13. 應付貿易賬項
As at the reporting date, aging analysis of trade payables 於報告日期，應付貿易賬項按
based on invoice date is as follows: 發票日期之賬齡分析如下：
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
12
–
7
17,567
17,586
31 December
2019
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
111
31–60 days 31–60天
0–30 days 0–30天
166
Over 60 days but less than 1 year超過60天但少於1年
322
1 year or over 1 year 1年或1年以上
19,039
19,638
General credit terms granted by suppliers are 30 days to 供應商授出之一般信貸期介乎
60 days. 30天至60天。
14. OTHER BORROWING 14. 其他借款
Initially in 2019, Mr. Xiong Qiangen granted a facility 於二零一九年，熊千根先生
of HK$100 million to the Group. The borrowing was 初步向本集團授出貸款融資
bearing 8% interest per annum and repayable on or 100,000,000港元。借款為按
before 31 March 2020. The Group provided a guarantee 年利率8%計息並須於二零二
and indemnity for the account of Mr. Xiong Qiangen in 零年三月三十一日或之前償
favour of a third party financial institution with financial 還。本集團為熊千根先生向
exposure capped at HK$8 million. On 17 March 2020, the 一家第三方金融機構提供擔
Group signed a supplementary agreement with Mr. Xiong 保及彌償，財務風險上限為
Qiangen to increase the facility amount from HK$100 8,000,000港元。於二零二零
million to HK$180 million and extend the repayment date 年三月十七日，本集團與熊千
from 31 March 2020 to 30 June 2021. The Group also 根先生簽署補充協議，將融資
entered into a deed of charge with Mr. Xiong Qiangen to 金額由100,000,000港元增至
charge the Group’s remaining 85% interest of financial 180,000,000港元，並將還款
assets at fair value through profit or loss in favour of 日期由二零二零年三月三十一
Mr. Xiong Qiangen as the security for repayment and 日延長至二零二一年六月三十
discharge of the other borrowing and all interest accrued 日。本集團亦與熊千根先生訂
and to be accrued thereon. On 2 April 2020, another 立抵押契據，將本集團餘下
supplementary agreement was signed to increase the 85%於按公平值於損益列賬
facilities amount from HK$180 million to HK$200 million. 之金融資產的權益以熊千根先
Part of the borrowing was applied to offset consideration 生為受益人進行抵押，作為還
receivable from Mr. Xiong in respect of disposal of interest 款及償還其他借款以及所有已
in the financial assets at fair value through profit and loss 產生及將產生利息的擔保。於
amount. 二零二零年四月二日，另一份
補充協議已獲簽署以將融資金
額由180,000,000港元增加至
200,000,000港元。部分借款
用以抵銷就出售按公平值於損
益列賬之金融資產的權益應收
熊先生的代價。
15.
CONVERTIBLE BONDS 15. 可換股債券
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
54,596
26,831
31 December
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
Liability component負債部分
Liability component of convertible 於二零二零年四月
bonds issued on 21 April 2020 二十一日發行按攤銷
measured at amortised costs成本計量的可換股
債券負債部分
–
Equity component權益部分
Equity component of convertible 於二零二零年四月
bonds issued on 21 April 2020 二十一日發行的
可換股債券權益部分
–
On 21 April 2020, the Company issued a three-year
zero coupon unsecured unlisted convertible bonds
(「Convertible Bonds」) with an aggregate principal amount
of HK$120,000,000.
The major terms of the Convertible Bonds are as follows:
(i)
The bondholders of the Convertible Bonds have
the right to convert all or any portion of the
Convertible Bonds into shares of the Company at
the conversion price of HK$0.20 per share (subject
to anti-dilutive adjustments). The conversion rights
can be exercised at any time throughout the term
of the Convertible Bonds.
(ii)
The Company may at any time from the issue date
to the maturity date, having given not less than
10 days』 notice to the bondholders, redeem all or
part of the Convertible Bonds on the day fixed for
redemption at such amount equivalent to 100%
of the principal amount of the outstanding bonds
(「Issuer’s Redemption Option」).
於二零二零年四月二十一日，
本公司發行三年期零票息無
抵押非上市可換股債券（「可
換股債券」），本金總額為
120,000,000港元。
可換股債券的主要條款如下：
(i)
可換股債券的債券持有
人有權按換股價每股
0.20港元（可進行反攤
薄調整）將全部或任何
部分可換股債券轉換為
本公司股份。換股權可
於可換股債券的期限內
任何時間行使。
(ii)
本公司可於發行日期至
到期日期間隨時通過向
債券持有人發出不少於
10天的通知，贖回當日
劃定為贖回的全部或部
分可換股債券，金額相
等於尚未償還債券本金
額的100%（「發行人贖
回權」）。
15. CONVERTIBLE BONDS (Cont』d)
The Convertible Bonds contain two components, the
liability and equity components. The initial fair value of
the two components was determined based on gross
proceeds at issuance. The initial fair value less allocated
transaction costs of the liability component was estimated
to be HK$79,754,000 as at 21 April 2020 (date of
issue) using the binomial option pricing model method,
taking into account the terms and conditions of the
Convertible Bonds, based on the valuation undertaken
by an independent professionally qualified valuer. The fair
value of the Issuer’s Redemption Option on the date of
initial recognition are considered insignificant based on
the valuation results. In subsequent periods, the liability
component is measured at amortised cost using effective
interest rate method. The effective interest rate of the
liability component of the Convertible Bonds is 14.59%
per annum. The residual amount less allocated transaction
costs representing the value of the equity component
of HK$40,246,000, was presented in equity under the
heading 「convertible bonds equity reserve」.
As at 30 June 2020, the outstanding principal amount of
the Convertible Bonds was HK$80,000,000.
Subsequent to 30 June 2020, in July 2020 all the
remaining principal amount of HK$80,000,000 were fully
converted into shares.
The movement of liability component and equity
component of the Convertible Bonds for the six months
ended 30 June 2020 is set out below:
15. 可換股債券（續）
可換股債券包含兩個部分，即
負債及權益部分。兩個部分的
初始公平值乃根據發行時所得
款項總額釐定。於二零二零年
四月二十一日（發行日期），按
照由獨立專業合資格估值師進
行的估值，採用二項式期權定
價模式法計算並考慮可換股債
券的條款及條件，負債部分的
初始公平值減獲分配的交易成
本估計為
79,754,000港元。根
據估值結果，發行人贖回權於
初步確認日期的公平值並不重
大。於其後期間，負債部分乃
採用實際利率法按攤銷成本計
量。可換股債券負債部分的實
際年利率為14.59%。剩餘金額
減獲分配的交易成本指權益部
分的價值
40,246,000港元，乃
於權益內「可換股債券權益儲
備」下呈列。
於二零二零年六月三十日，可
換股債券的尚未償還本金額為
80,000,000港元。
於二零二零年七月，即二零二
零年六月三十日後，全部剩餘
本金額
80,000,000港元可悉數
轉換為股份。
截至二零二零年六月三十日止
六個月的可換股債券負債部分
及權益部分的變動列載如下：
Liability component Equity component
(At amortised cost) (Residual amount)
負債部分權益部分
（按攤銷成本）（剩餘金額）
HK$』000 HK$』000
千港元千港元
At 21 April 2020 於二零二零年四月二十一日
(date of issue)（發行日期）
79,754 40,246
Interest accrued應計利息
1,740 –
Conversion換購股份
(26,898) (13,415)
At 30 June 2020於二零二零年六月三十日
54,596 26,831
16. SHARE CAPITAL 16. 股本
Number of
shares
股份數目
Nominal
value
面值
HK$』000
千港元
Ordinary share of HK$0.2 each每股面值0.2港元的普通股
Authorised: 法定：
At 31 December 2019, 於二零一九年十二月三十一日、
1 January 2020 and 30 June 二零二零年一月一日及二零二零
2020年六月三十日
5,000,000,000 1,000,000
Issued and fully paid:已發行及繳足：
At 31 December 2019 and 於二零一九年十二月三十一日及
1 January 2020二零二零年一月一日
879,289,500 175,858
Share placing (note (ii))股份配售（附註(ii)）
500,000,000 100,000
Conversion of convertible bonds 轉換可換股債券（附註(ii)）
(note (ii))200,000,000 40,000
At 30 June 2020於二零二零年六月三十日
1,579,289,500 315,858
Notes: 附註：
(i) All these ordinary shares issued by the Company (i) 本公司於各年度發行之
during the years rank pari passu with the then 所有普通股於各方面均
existing ordinary shares in all respects. 與當時之現有普通股享
有同等權益。
(ii) In May 2020, upon the completion of share (ii) 於二零二零年五月，
placing, 500,000,000 new shares of the 股份配售完成後，本
Company were issued at HK$0.2 per share. The 公司按每股0.2港元發
Company also allotted and issued 200,000,000 行
500,000,000股新股
ordinary shares to the holder of convertible bonds 份。由於本公司已收
as the Company received conversion notices 到與以每股0.2港元的
in respect of the conversion of the convertible 換股價轉換本金額為
bonds with principal amount of HK$40,000,000 40,000,000港元的可
at the conversion price of HK$0.2 per share. 換股債券有關的轉換通
知，故本公司亦已向可
換股債券持有人配發及
發行
200,000,000股普
通股。
17. CAPITAL AND OTHER COMMITMENTS 17. 資本及其他承擔
30 June
2020
二零二零年
六月三十日
HK$』000
千港元
Unaudited
未經審核
652
31 December
2019
二零一九年
十二月三十一日
HK$』000
千港元
Audited
經審核
Capital commitments:資本承擔：
Contracted but not provided for:已訂約但未撥備：
Purchase of property, plant 購置物業、廠房及
and equipment and others設備及其他
654
The Company signed two sponsorship agreements with 本公司與牛津大學就幹細胞
the University of Oxford on the research of stem cell 治療及組織工程的研究訂立
therapy and tissue engineering. The Company agreed 兩份贊助協議。本公司同意於
to pay GBP9.0 million (equivalent to HK$86 million) 協議涵蓋期間向牛津大學分期
to the University of Oxford by instalments over the 支付
9,000,000英鎊（相當於
period covered by agreements. Up to 30 June 2020, 86,000,000港元）。截至二零
the Company has paid GBP5.05 million (equivalent to 二零年六月三十日，本公司已
HK$55.9 million) to the University of Oxford. 向牛津大學支付5,050,000英鎊
（相當於55,900,000港元）。
18. SHARE OPTION SCHEME 18. 購股權計劃
A share option scheme was adopted by the Company 本公司根據一項於二零一一年
pursuant to a resolution passed on 14 September 2011 九月十四日通過之決議案採納
(the 「Scheme」). Under the Scheme, the Board may grant 一項購股權計劃（「計劃」）。
options to (i) any eligible employee (means any employee, 根據計劃，董事會可向下列人
whether full time or part time, including any executive 士授出購股權以認購本公司股
directors and non-executive directors) of the Company, 份：(i)本公司、其任何附屬公
any of its subsidiaries and any invested entity; (ii) any 司及任何所投資實體之任何合
supplier of goods or services to any member of the Group 資格僱員（指任何全職或兼職僱
or any invested entity; (iii) any customer of the Group or 員，包括任何執行董事及非執
any invested entity; (iv) any person or entity that provides 行董事）；(ii)向本集團任何成員
research, development or technological support or other 公司或任何所投資實體供應貨
services to the Group or any invested entity; and (v) any 品或服務之任何供應商；
(iii)本
shareholder or any member of the Group or any invested 集團或任何所投資實體之任何
entity or any holder of any securities issued by any 客戶；
(iv)向本集團或任何所投
member of the Group to any invested entity (collectively 資實體提供研究、開發或技術
known as the 「Participants」), to subscribe for shares in the 支援或其他服務之任何人士或
Company. 實體；及
(v)本集團任何股東或
任何成員公司或任何所投資實
體或本集團任何成員公司向任
何所投資實體發行之任何證券
之任何持有人（統稱「參與者」）。
18. SHARE OPTION SCHEME (Cont』d) 18. 購股權計劃（續）
Movement in share options: 購股權變動：
During the six months ended 30 June 2020, no new 截至二零二零年六月三十日止
options were granted under the scheme (Year ended 31 六個月，並無根據計劃授出新
December 2019: Nil). 購股權（截至二零一九年十二月
三十一日止年度：無）。
30 June 2020 31 December 2019
二零二零年六月三十日二零一九年十二月三十一日
Weighted
average
exercise
price
Number
of options
加權平均
行使價購股權數目
HK$ 』000
港元千份
Unaudited
未經審核
7.09 8,874
7.46 (372)
7.07 8,502
Weighted
average
exercise Number
price of options
加權平均
行使價購股權數目
HK$ 』000
港元千份
Audited
經審核
Outstanding at beginning of 期初╱年初尚未行使
period/year
7.08 10,932
Forfeited/Lapsed during the period期內沒收╱失效
7.09 (2,058)
7.09 8,874
Outstanding at end of period/year期末╱年末尚未行使
As at 30 June 2020, the weighted average remaining 於二零二零年六月三十日，尚
contractual life for the outstanding share options is 5.21 未行使購股權的加權平均剩餘
years (31 December 2019: 5.70 years). 合約年期為5.21年（二零一九年
十二月三十一日：5.70年）。
MANAGEMENT DISCUSSION AND ANALYSIS
管理層討論及分析
BUSINESS REVIEW AND FUTURE
PROSPECT
The Group continues to strive for opportunity to widen its
business scope in the medicine industries and reallocate
its resources when appropriate, to strengthen and maintain
as one of the leading pioneer in the medical and related
industries. The Chinese government has committed to
provide support towards hi-tech industries, including
regenerative medicine, a sub-division of the bio-medical
industries. We will continuously strive for more assistance
from the Chinese government to provide additional
resources for broadening our R&D coverage in regenerative
medicine and related medical device spectrum. Stem
cell therapy and research and development of stem cell
pharmaceutical products, precision disease detection and
prevention in massive health as well as precision treatment
have continued to develop.
The Company has made its best effort to improve the
Group’s operational performance and to extend the
Group’s sale network in the PRC, especially in the
healthcare products and services segment and as a
result, the performance of the healthcare products and
services segment in the second quarter of 2020 has
substantially improved and generated operating profit
and improved the liquidity of the Group. The extended
sale network is expected to improve the profitability of the
business of the Group for the years coming. The Group
will continue to make effort to implement measures
to improve the Group’s operational performance and
financial position. The Board will continuously evaluate
the business environment, the existing business portfolio
and income streams of the Group and improve the
profitability of the Group.
The Company will continue to implement measures
aiming at improving the working capital and cash flows
of the Group, including close monitoring of general
administrative expenses and operating costs and
soliciting more potential customers. The Company may
also consider disposing of non-profit making businesses
and to review its plan of acquisition in order to reduce
operating costs and improve working capital. In June
2020, the Group cancelled a proposed acquisition, and
the deposit of HK$46,512,000 has been and will be
returned to the Group by stages with last portion thereof
be returned by December 2020.
The Company will also consider alternative means of
fund raising which may or may not involve issuance of
shares or convertible bonds of the Company and/or the
realization of assets, financial assets or otherwise.
業務回顧及未來前景
本集團將繼續爭取擴大其於醫學
行業之業務範圍的機會，並適時
重新分配其資源以加強和維持其
在醫學及相關行業的領先地位。
中國政府致力對高新技術產業提
供支持，包括作為生物醫藥產業
分支的再生醫學。我們將繼續爭
取獲得中國政府更多的支持，為
擴大我們於再生醫學及相關醫療
器械領域之研發範圍提供額外資
源。幹細胞療法與幹細胞藥品研
發、大健康領域的精準疾病檢測
與防禦及精準治療持續發展。
本公司已竭盡所能改善本集團的
經營業績及擴大本集團的中國銷
售網絡，尤其是在大健康產品及
服務分部，因此，於二零二零年
第二季度，大健康產品及服務分
部的業績顯著改善，並產生經營
溢利，改善本集團的流動資金狀
況。經擴大的銷售網絡預期將於
未來數年可提高本集團業務的盈
利能力。本集團將繼續致力實施
改善本集團的經營業績及財務狀
況的措施。董事會將持續評估本
集團的營商環境、現有業務組合
及收入來源，並提高本集團的盈
利能力。
本公司將繼續採取旨在改善本集
團營運資金及現金流量的措施，
包括嚴密監控一般行政開支及營
運成本，並招攬更多潛在客戶。
本公司亦可能考慮出售非營利性
業務，並檢討其收購計劃，以降
低營運成本及改善營運資金。於
二零二零年六月，本集團取消一
項建議收購事項，按46,512,000
港元已經及將會分期退還予本集
團，最後一期將於二零二零年十
二月前退還。
本公司亦將考慮可能涉及或不涉
及發行本公司股份或可轉換債券
的其他集資方式及╱或變現資
產、金融資產或其他的融資方式。
FINANCIAL REVIEW
RESULTS OF THE GROUP
Revenue
The Group’s revenue for the six months period
ended 30 June 2020 was approximately HK$68.9
million, representing an increase of approximately
HK$46.5 million, or 207.6%, compared to revenue of
approximately HK$22.4 million for the same period of
last year. The overall increase in revenue was primarily
attributable to the increase in revenue in the segment of
healthcare products and services. This was due to the
extension of sales network in the PRC.
Cost of sales
Cost of sales of the Group increased by approximately
23.8% from approximately HK$12.6 million for the six
months ended 30 June 2019 to approximately HK$15.6
million for the six months ended 30 June 2020. The
increase was mainly in line with increase in revenue of the
healthcare products and services segment.
Gross profit and margin
The Group recorded a gross profit of approximately
HK$53.3 million for the six months ended 30 June 2020,
representing an increase of approximately 443.9% as
compared to the gross profit as recorded in the prior
period of approximately HK$9.8 million, as the Group
focused its effort on business of higher margin.
Other income
Other income of the Group increased by approximately
6.1%, from approximately HK$11.4 million for the six
months ended 30 June 2019 to approximately HK$12.1
million for the six months ended 30 June 2020. Other
income mainly comprised of the gain on disposal of
financial assets at fair value through profit or loss of
approximately HK$2.3 million, the gain on modification of
lease of approximately HK$6.2 million and government
grant income of approximately HK$2.4 million.
財務回顧
集團業績
收益
本集團截至二零二零年六月三
十日止六個月期間之收益約為
68,900,000港元，較去年同期收
益約
22,400,000港元，增加約
46,500,000港元或207.6%。收益
整體增加主要由於大健康產品及
服務分部之收益增加。此乃由於
中國銷售網絡擴張。
銷售成本
本集團的銷售成本由截至二零
一九年六月三十日止六個月約
12,600,000港元增加約23.8%至
截至二零二零年六月三十日止六
個月約15,600,000港元。該增加
大致上與大健康產品及服務分部
的收益增幅同步。
毛利及毛利率
本集團截至二零二零年六月
三十日止六個月錄得毛利約
53,300,000港元，較過往期間錄
得的毛利約9,800,000港元增加約
443.9%，因本集團著力推展有更
高利潤的業務。
其他收入
本集團的其他收入由截至二零
一九年六月三十日止六個月約
11,400,000港元增加約
6.1%至
截至二零二零年六月三十日止六
個月約
12,100,000港元。其他
收入主要包括出售按公平值於
損益列賬之金融資產之收益約
2,300,000港元、修改租賃之收益
約6,200,000港元及政府補貼收入
約2,400,000港元。
FINANCIAL REVIEW (Cont』d)
RESULTS OF THE GROUP (Cont』d)
Selling and distribution expenses
Selling and distribution expenses of the Group increased
by approximately 243.4%, from approximately HK$14.3
million for the six months ended 30 June 2019 to
approximately HK$49.1 million for the six months ended
30 June 2020 which was attributable to the increase in
meticulous effort to boost revenue.
Administrative and other expenses
Administrative and other expenses of the Group
increased by approximately 121.0%, from approximately
HK$84.6 million for the six months ended 30 June 2019
to approximately HK$187.0 million for the six months
ended 30 June 2020. The increase was mainly due to the
increase in staff costs and lease expenses.
Net assets
Net assets of the Group amounted to approximately
HK$13.8 million as at 30 June 2020, as compared to net
assets of approximately HK$17.6 million at 31 December
2019. The change was mainly attributable to the net
effect of loss incurred and funds raised during the period.
Cash and bank balances
As at 30 June 2020, the Group had cash and bank
balances of approximately HK$28.5 million (31 December
2019: HK$19.2 million).
Working Capital and Gearing Ratio
As at 30 June 2020, the Group had current assets of
approximately HK$330.1 million (31 December 2019:
approximately HK$344.0 million), while current liabilities
of approximately HK$311.5 million (31 December 2019:
approximately HK$301.2 million), representing a net
current liabilities position with a working capital ratio
(current assets to current liabilities) of 1.06 (31 December
2019: 1.14).
The gearing ratio of the Group as at 30 June 2020,
calculated as total bank and other borrowings to total
equity was 5.1 (31 December 2019: 3.1).
財務回顧（續）
集團業績（續）
銷售及分銷開支
本集團的銷售及分銷開支由截至
二零一九年六月三十日止六個月
約14,300,000港元增加約243.4%
至截至二零二零年六月三十日止
六個月約49,100,000港元，歸因
於加大精準增加收益的力度。
行政及其他開支
本集團的行政及其他開支由截至
二零一九年六月三十日止六個月
約84,600,000港元增加約121.0%
至截至二零二零年六月三十日止
六個月約187,000,000港元。該
增加乃主要由於員工成本及租賃
開支增加。
淨資產
於二零二零年六月三十日，本集
團之淨資產約為
13,800,000港
元，而於二零一九年十二月三十
一日之淨資產約為17,600,000港
元。該變動乃主要由於期內產生
虧損與籌集資金的淨影響。
現金及銀行結餘
於二零二零年六月三十日，本
集團擁有現金及銀行結餘約
28,500,000港元（二零一九年十二
月三十一日：19,200,000港元）。
營運資金比率及資產負債比率
於二零二零年六月三十日，本
集團流動資產約為330,100,000
港元（二零一九年十二月三十一
日：約
344,000,000港元），而流
動負債約為
311,500,000港元（二
零一九年十二月三十一日：約
301,200,000港元），即處於淨流
動負債狀況，而營運資金比率（流
動資產比流動負債）為1.06（二零
一九年十二月三十一日：1.14）。
於二零二零年六月三十日，本集
團之資產負債比率（銀行及其他借
款總額比總權益）為5.1（二零一九
年十二月三十一日：3.1）。
USE OF PROCEEDS 所得款項用途
The following table sets out the actual use of the net 下表載列截至二零二零年六月三
proceeds from the fund raising exercises for the six 十日止六個月，集資活動所得款
months ended 30 June 2020: 項淨額之實際用途：
Date of Proposed use of Total net
announcement Fund raising activities the net proceeds proceeds Utilised Unutilised
所得款項淨額之所得款項
公告日期集資活動建議用途淨額總額已動用未動用
(HK$ Million) (HK$ Million) (HK$ Million)
（百萬港元）（百萬港元）（百萬港元）
2 March 2020,
27 March 2020,
15 April 2020 and
15 May 2020
二零二零年
三月二日、
二零二零年
三月二十七日、
Placing of 500,000,000
new shares under a
specific mandate
根據特別授權配售
500,000,000股新股份
(a) Settlement of accrued
charges and other payables
(a) 支付應計費用及其他應付
款項
(b) Staff costs
(b) 員工成本
30.00
30.00
30.00
30.00
–
–
二零二零年
四月十五日及
二零二零年
(c) Rent and rates
(c) 租金及差餉
5.00 5.00 –
五月十五日
(d) Utility and other expenses
(d) 水電及其他開支
5.00 5.00 –
(e) Professional fees and
corporate expenses
(e) 專業費及企業開支
9.00 9.00 –
(f) Advertising, marketing and
promotion expenses
(f) 廣告、營銷及宣傳開支
19.00 19.00 –
98.00 98.00 –
Date of Proposed use of Total net
announcement Fund raising activities the net proceeds proceeds Utilised Unutilised
所得款項淨額之所得款項
公告日期集資活動建議用途淨額總額已動用未動用
(HK$ Million) (HK$ Million) (HK$ Million)
（百萬港元）（百萬港元）（百萬港元）
6 January 2020 and
20 January 2020
二零二零年
一月六日及
二零二零年
一月二十日
Disposal of 15%
investment in Class B
Interests of the Zhong
Hua Finance Acquisition
Fund I, L.P.
出售Zhong Hua Finance
Acquisition Fund I, L.P.
B類權益的15%投資
(a) Staff costs
(a) 員工成本
(b) Rent and rates
(b) 租金及差餉
(c) Utility and other expenses
(c) 水電及其他開支
4.50
17.50
8.30
4.50
17.50
8.30
–
–
–
(d) Professional fees and
corporate expenses
(d) 專業費及企業開支
0.44 0.44 –
(e) Advertising, marketing and
promotion expenses
(e) 廣告、營銷及宣傳開支
14.50 14.50 –
45.24 45.24 –
Date of Proposed use of Total net
announcement Fund raising activities the net proceeds proceeds Utilised Unutilised
所得款項淨額之所得款項
公告日期集資活動建議用途淨額總額已動用未動用
(HK$ Million) (HK$ Million) (HK$ Million)
（百萬港元）（百萬港元）（百萬港元）
21 February 2020,
7 May 2020 and
29 May 2020
二零二零年
二月二十一日、
二零二零年
五月七日及
二零二零年
五月二十九日
Further disposal of 85%
investment in Class B
Interests of the Zhong
Hua Finance Acquisition
Fund I, L.P.
進一步出售Zhong Hua
Finance Acquisition
Fund I, L.P. B類權益的
85%投資
(a) Settlement of trade
payables
(a) 支付應付貿易賬項
(b) Settlement of accrued
charges and other payables
(b) 支付應計費用及其他應付
款項
19.50
50.50
–
2.00
19.50
48.50
(c) Settlement of other
borrowing
(c) 支付其他借款
56.80 56.80 –
(d) Staff costs
(d) 員工成本
62.50 1.70 60.80
(e) Rent and rates
(e) 租金及差餉
5.50 2.50 3.00
(f) Utility and other expenses
(f) 水電及其他開支
11.70 1.50 10.20
(g) Professional fees and
corporate expenses
(g) 專業費及企業開支
15.50 1.50 14.00
(h) Advertising, marketing and
promotion expenses
(h) 廣告、營銷及宣傳開支
33.20 33.20 –
255.20（附註）
99.20 156.00（附註）
Note:
Of the balance of the proceeds of HK$156 million 附註：所得款項結餘
156,000,000港
receivable, HK$78 million is receivable on or before 30 元中，
78,000,000港元於二
September 2020; and HK$78 million is receivable on or 零二零年九月三十日或之前應
before 30 December 2020.收，78,000,000港元於二零二
零年十二月三十日或之前應收。
SEGMENTAL INFORMATION
Segmental information of the Group is set out in note 4 to
the financial statements.
FOREIGN EXCHANGE EXPOSURE
The Group’s business transactions, assets and liabilities
are principally denominated in Renminbi and Hong
Kong dollars. The Directors consider the risk of foreign
exchange exposure of the Group is manageable.
The management will continue to monitor the foreign
exchange exposure of the Group and is prepared to take
prudent measures such as hedging when appropriate
actions are required.
BANK BORROWINGS AND
CONTINGENT LIABILITIES
As at 30 June 2020, all bank borrowings were fully
repaid.
As at 30 June 2020, the Group had no material
contingent liabilities (31 December 2019: Nil).
CHARGES ON GROUP ASSETS
As at 30 June 2020, there is no charge on the assets
of the Group to secure the bank borrowings and the
banking facilities of the Group.
SIGNIFICANT INVESTMENT,
MATERIAL ACQUISITIONS/
DISPOSAL OF SUBSIDIARIES AND
AFFILIATED COMPANIES
The Group has no significant investment, material
acquisitions/disposals of subsidiaries and affiliated
companies during the period.
DETAILS OF FUTURE PLANS
FOR MATERIAL INVESTMENT OR
CAPITAL ASSETS
The Group has no future plan for material investment or
capital assets.
分部資料
本集團之分部資料載於財務報表
附註4。
外匯風險
本集團的業務交易、資產及負債
主要以人民幣及港元計值。董事
認為本集團之外匯風險受控。管
理層將繼續監控本集團的外匯風
險，並於情況有需要時採取對沖
等審慎措施。
銀行借款及或有負債
於二零二零年六月三十日，所有
銀行借款已全數還清。
於二零二零年六月三十日，本集
團並無重大或有負債（二零一九年
十二月三十一日：無）。
本集團資產抵押
於二零二零年六月三十日，本集
團並無抵押資產作為本集團銀行
借款及銀行融資的抵押。
重大投資、附屬公司
及聯屬公司之重大收
購╱出售事項
本集團期內概無重大投資、重大
收購╱出售附屬公司及聯屬公司。
重大投資或資本資產
未來計劃之詳情
本集團並無重大投資或資本資產
之未來計劃。
EMPLOYEE INFORMATION AND
REMUNERATION POLICY
As at 30 June 2020, the Group had 369 (30 June 2019:
316) employees located in Hong Kong and Mainland
China. As an equal opportunity employer, the Group’s
remuneration and bonus policies are determined with
reference to the performance and experience of individual
employees. The total amount of employee remuneration
(including that of the Directors and retirement benefits
scheme contributions) of the Group for the period
was approximately HK$84.2 million (30 June 2019:
approximately HK$38.5 million).
In addition, the Group may offer options to employees
as a recognition of and reward for their efforts and
contributions to the Group.
EVENTS AFTER THE REPORT
PERIOD
Events after 30 June 2020 not stated elsewhere in this
report:
(i) On 22 July 2020, 280,000,000 shares were issued
and allotted upon conversion of Convertible Bonds
with principal amount of HK$56,000,000.
(ii) On 27 July 2020, 120,000,000 shares were issued
and allotted upon conversion of Convertible Bonds
with principal amount of HK$24,000,000.
僱員資料及薪酬政策
於二零二零年六月三十日，本集
團共有僱員369名（二零一九年六
月三十日：
316名），分佈於香港
及中國內地。本集團為提供均等
機會的僱主，其薪酬及獎金政策
乃經參考僱員之個別表現及經驗
而釐定。期內本集團之僱員薪酬
總額（包括董事薪酬及退休福利
計劃供款）約為84,200,000港元
（二零一九年六月三十日：約為
38,500,000港元）。
此外，本集團亦可向僱員授出購
股權以肯定及獎勵他們的努力及
對本集團作出的貢獻。
報告期後的事件
本報告其他部分未有述明的二零
二零年六月三十日後的事件：
(i)
於二零二零年七月二十二日，
280,000,000股股份在本金額
為56,000,000港元的可換股債
券獲轉換後發行及配發。
(ii)
於二零二零年七月二十七日，
120,000,000股股份在本金額
為24,000,000港元的可換股債
券獲轉換後發行及配發。
OTHER INFORMATION
其他資料
DIRECTORS』 AND CHIEF
EXECUTIVES』 INTERESTS AND
SHORT POSITIONS IN SHARES
AND UNDERLYING SHARES
As at 30 June 2020, the following Directors and chief
executives of the Company had or were deemed to
have interest or short positions in the shares, underlying
shares or debentures of the Company and its associated
corporations (within the meaning of Part XV of the
Securities and Futures Ordinance (Chapter 571 of the
Laws of Hong Kong) (the 「SFO」)) (i) which were required
to be notified to the Company and the Stock Exchange
pursuant to Divisions 7 and 8 of Part XV of the SFO
(including interests or short positions which they were
taken or deemed to have under such provisions of the
SFO); or (ii) which were required, pursuant to Section
352 of the SFO, to be entered in the register referred to
therein; or (iii) which were, pursuant to Rules 5.46 to 5.67
of the GEM Listing Rules related to securities transactions
by the Directors to be notified to the Company and the
Stock Exchange:
LONG POSITIONS
Interests in the shares and underlying shares
of the Company
董事及最高行政人員
於股份及相關股份之
權益及淡倉
於二零二零年六月三十日，下列
董事及本公司最高行政人員於本
公司及其相聯法團（定義見香港法
例第571章證券及期貨條例（「證
券及期貨條例」）第XV部）之股
份、相關股份或債權證中，擁有
或被視作擁有
(i)根據證券及期貨
條例第XV部第7及8分部須知會本
公司及聯交所之權益或淡倉（包括
彼等根據證券及期貨條例有關條
文被當作或視作擁有之權益或淡
倉）；或
(ii)根據證券及期貨條例第
352條須記入該條所述登記冊之
權益或淡倉；或
(iii)根據GEM上市
規則第5.46至5.67條有關董事進
行證券交易之規定須知會本公司
及聯交所之權益或淡倉：
好倉
於本公司股份及相關股份之權
益
Approximate
Aggregate long percentage of
position in the the issued
shares and share capital
Name Capacity underlying shares as at 30 June 2020
佔於二零二零年
六月三十日
於股份及相關股份之已發行股本
姓名身份好倉總計概約百分比
Mr. Wang Chuang Beneficial owner 25,140,000 1.59%
王闖先生實益擁有人
Mr. Wu Weiliang Beneficial owner 22,620,000 1.43%
吳偉良先生實益擁有人
Save as disclosed above, as at 30 June 2020, none of the
Directors nor the chief executives of the Company had
or was deemed to have any interests or short positions
in the shares, underlying shares or debentures of the
Company and its associated corporations (within the
meaning of Part XV of the SFO) (i) which were required
to be notified to the Company and the Stock Exchange
pursuant to Divisions 7 and 8 of Part XV of the SFO
(including interests or short positions which they were
taken or deemed to have under such provisions of the
SFO); or (ii) which were required, pursuant to Section
352 of the SFO, to be entered in the register referred
to therein; or (iii) which were, pursuant to Rules 5.46
to 5.67 of the GEM Listing Rules relating to securities
transactions by Directors to be notified to the Company
and the Stock Exchange.
SUBSTANTIAL SHAREHOLDERS』
AND OTHER PERSONS』
INTERESTS IN SHARES AND
UNDERLYING SHARES
So far as known to the Directors, as at 30 June 2020,
the following parties (not being the Directors or chief
executives of the Company) had, or were deemed to
have, interests or short positions in the shares, underlying
shares or debentures of the Company (i) which would fall
to be disclosed to the Company and the Stock Exchange
under the provisions of Divisions 2 and 3 of Part XV of
the SFO; or (ii) which were required, pursuant to Section
336 of the SFO, to be entered in the register referred to
therein:
除上文所披露者外，於二零二零
年六月三十日，概無董事或本公
司最高行政人員於本公司及其相
聯法團（定義見證券及期貨條例第
XV部）之股份、相關股份或債權
證中擁有或視作擁有任何
(i)根據
證券及期貨條例第XV部第7及8分
部須知會本公司及聯交所之權益
或淡倉（包括彼等根據證券及期貨
條例有關條文被當作或視作擁有
之權益或淡倉）；或
(ii)根據證券及
期貨條例第352條須記入該條所
述登記冊之權益或淡倉；或
(iii)根
據GEM上市規則第5.46至5.67條
有關董事進行證券交易之規定須
知會本公司及聯交所之權益或淡
倉。
主要股東及其他人士
於股份及相關股份之
權益
據董事所知，於二零二零年六月
三十日，下列人士（非董事或本公
司最高行政人員）於本公司股份、
相關股份或債券中，擁有或被視
作擁有
(i)根據證券及期貨條例第
XV部第2及3分部之條文須向本公
司及聯交所披露之權益或淡倉；
或(ii)根據證券及期貨條例第336條
須記入該條所述登記冊內之權益
或淡倉：
LONG POSITIONS 好倉
Interests in the shares and underlying shares of the 於本公司股份及相關股份之權益
Company
Name of Shareholders Capacity
Aggregate long
position in the
shares and
underlying shares
Approximate
percentage of
the issued
share capital
as at 30 June 2020
佔於二零二零年
六月三十日
於股份及相關已發行股本
股東姓名╱名稱身份股份之好倉總計概約百分比
Substantial Shareholders
主要股東
All Favour Holdings
Limited (Note 1)
全輝控股有限公司（附註1）
Mr. Dai Yumin (Note 1)
戴昱敏先生（附註1）
Mr. Xu Yi (Note 1)
徐毅先生（附註1）
Mr. Mao Xiao Kai
毛曉凱先生
Persons other than Substantial
Shareholders
主要股東以外之人士
China Orient Asset Management
Co., Ltd (Note 2)
中國東方資產管理股份
有限公司（附註2）
China Orient Alternative
Investment Fund
(Note 2)（附註2）
Chung Lee Securities
Company Limited (Note 3)
眾利股票有限公司（附註3）
Zhonghua Financial Holdings
Limited (Note 3)
中華金融控股有限公司（附註3）
Mr. Xie Yong (Note 3)
謝勇先生（附註3）
Beneficial owner
實益擁有人
Held by controlled
corporation
由受控法團持有
Beneficial owner
實益擁有人
Held by controlled
corporation
由受控法團持有
Beneficial owner
實益擁有人
Held by controlled
corporation
由受控法團持有
Held by controlled
corporation
由受控法團持有
Beneficial owner
實益擁有人
Held by controlled
corporation
由受控法團持有
Held by controlled
corporation
由受控法團持有
462,907,765 29.31%
462,907,765 29.31%
875,000 0.06%
462,907,765 29.31%
160,000,000 10.13%
157,744,659 9.99%
157,744,659 9.99%
120,000,000 7.60%
120,000,000 7.60%
120,000,000 7.60%
Notes: 附註：
1. All Favour Holdings Limited (「All Favour」) is beneficially 1. 全輝控股有限公司（「全輝」）由
owned as to (i) 40% by Nat-Ace Wood Industry Ltd. (「Nat-
Ace Wood Industry」) and 20% by Honour Top Holdings
Limited, of which Nat-Ace Wood Industry is ultimately
and wholly-owned by Mr. Xu Yi (「Mr. Xu」) and Honour
Top Holdings Limited is ultimately wholly owned by Mr.
Dai Yumin (「Mr. Dai」), and (ii) 40% by Mr. Dai. Moreover,
All Favour has been the beneficial owner of 462,907,765
Shares. By virtue of the SFO, Mr. Dai, Mr. Xu and Nat-
Ace Wood Industry are deemed to be interested in
462,907,765 Shares in which All Favour is interested in.
On 16 September 2015, Mr. Dai was granted 17,500,000
share options by the Company under the share option
scheme adopted by the Company on 14 September
2011 entitling him to subscribe for 17,500,000 Shares at
the exercise price of HK$0.45 per Share, subject to the
terms and conditions of the share option scheme of the
Company. The number of Shares to be issued upon full
exercise of the said share options and the exercise price
per Share were adjusted to 875,000 Shares and HK$9.00
per Share with effect from 16 May 2019 as a result of the
share consolidation of the Company, details of which were
disclosed in the announcement of the Company dated 15
May 2019. Assuming the share options granted to Mr. Dai
has been exercised in full, Mr. Dai shall hold an aggregate
of 875,000 Shares as beneficial owner. By virtue of the
SFO, Mr. Dai, together with his deemed interests in All
Favour, was deemed to be interested in an aggregate
of 463,782,765 shares of the Company. All Favour has
pledged its interests in 157,744,659 Shares in favour of
Optimus.
(i)邦強木業有限公司（「邦強木
業」）實益擁有
40%及Honour
Top Holdings Limited實益擁
有20%，其中邦強木業由徐毅
先生（「徐先生」）最終及全資擁
有，而
Honour Top Holdings
Limited由戴昱敏先生（「戴先
生」）最終全資擁有，及(ii)戴先
生實益擁有40%。此外，全
輝為462,907,765股股份之實
益擁有人。根據證券及期貨條
例，戴先生、徐先生及邦強
木業被視為於全輝擁有權益
的462,907,765股股份中擁有
權益。於二零一五年九月十
六日，戴先生獲本公司根據
本公司於二零一一年九月十
四日採納之購股權計劃授予
17,500,000份購股權，賦予其
權利可按每股0.45港元之行使
價認購
17,500,000股股份，惟
須遵守本公司購股權計劃之條
款及條件。本公司的股份合併
令於悉數行使上述購股權時將
予發行之股份數目及每股行使
價分別調整為875,000股股份
及每股9.00港元，自二零一九
年五月十六日起生效，有關詳
情披露於本公司日期為二零一
九年五月十五日之公告。假設
授予戴先生之購股權獲悉數行
使，戴先生將作為實益擁有人
持有合共875,000股股份。根
據證券及期貨條例，連同彼被
視為於全輝擁有之權益，戴先
生被視為於合共463,782,765
股本公司股份中擁有權益。全
輝已將其於157,744,659股股
份中的權益抵押予Optimus。
2.
Based on the disclosure of interests form both filed on 25 2. 根據中國東方資產管理股份有
January 2018 by China Orient Asset Management Co., 限公司（「東方資產」）及China
Ltd (「COAMC」) and China Orient Alternative Investment Orient Alternative Investment
Fund (「COAIF」), Optimus Prime Management Ltd. Fund（「COAIF」）於二零一八
(「Optimus」) has a security interest in 262,907,765 Shares 年一月二十五日提交的權益
and China Orient Asset Management (International) 披露表格，
Optimus Prime
Holding Limited (「COAMI」) has an interest in 19,200,000 Management Ltd.（「Optimus」）
Shares. Optimus is wholly owned by COAIF. COAIF is 於262,907,765股股份中持有
owned as to 45% by COAMI. COAMI is owned as to (i) 保證權益且中國東方資產管理
50% by Wise Leader Assets Ltd. (「Wise Leader」) which （國際）控股有限公司（「東方國
is wholly owned by Dong Yin Development (Holdings) 際」）於
19,200,000股股份中
Limited (「Dong Yin」); and (ii) 50% by Dong Yin which 擁有權益。Optimus由COAIFis wholly owned by COAMC. By virtue of the SFO, 全資擁有。COAIF則由東方國
Wise Leader, Dong Yin and COAMC are deemed to be 際擁有45%。東方國際分別
interested in 19,200,000 Shares held by COAMI, and 由
(i) Wise Leader Assets Ltd.
COAIF, COAMI, Wise Leader, Dong Yin and COAMC are （「Wise Leader」，由東銀發
deemed to be interested in 262,907,765 Shares held by 展（控股）有限公司（「東銀」）
Optimus as security interest. As a result, Wise Leader, 全資擁有）擁有50%；及(ii)東
Dong Yin and COAMC are deemed to be interested in 銀（由東方資產全資擁有）擁
an aggregate of 262,907,765 Shares. Based on the 有50%。根據證券及期貨條
disclosure of interests form both filed on 7 January 2020 例，Wise Leader、東銀及東
by COAMC and COAIF, Optimus has decreased its 方資產被視為於東方國際所
security interest to 157,744,659 Shares and COAMI has 持有的19,200,000股股份中
remained its interest of 19,200,000 Shares. Based on the 擁有權益，而COAIF、東方國
disclosure of interests form filed on 24 January 2020 by 際、Wise Leader、東銀及東
COAMC, COAMC has an interest of 157,794,659 Shares 方資產被視為於
Optimus持作
and COAMI ceased to have an interest in 19,200,000 保證權益的262,907,765股股
Shares. 份中擁有權益。因此，Wise
Leader、東銀及東方資產被
視為於合共262,907,765股股
份中擁有權益。根據東方資
產及COAIF於二零二零年一月
七日提交的權益披露表格，
Optimus將其保證權益減少至
157,744,659股股份及東方資
產維持其19,200,000股股份
的權益。根據東方資產於二零
二零年一月二十四日提交的權
益披露表格，東方資產持有
157,794,659股股份的權益，
東方資產不再於
19,200,000股
股份中擁有權益。
3.
Based on the disclosure of interests forms filed on 15 May 3.根據眾利股票有限公司（「眾
2020 by Chung Lee Securities Company Limited (「Chung 利」）、中華金融控股有限公司
Lee」), Zhonghua Financial Holdings Limited (「ZFHL」) and （「中華金融」）及謝勇先生（「謝
Mr. Xie Yong (「Mr. Xie」), Chung Lee is beneficially owned 先生」）於二零二零年五月十五
as to 100% by ZFHL, and ZFHL is beneficially owned as 日提交的權益披露表格，眾利
to 34% by Mr. Xie. By virtue of SFO, ZFHL and Mr. Xie are 由中華金融實益擁有100%，
deemed to be interested in 120,000,000 shares in which 而中華金融由謝先生實益擁有
Chung Lee is interested in. 34%。根據證券及期貨條例，
中華金融及謝先生均被視為於
眾利擁有權益的120,000,000
股股份中擁有權益。
Save as disclosed above, as at 30 June 2020, the
Directors are not aware that there is any other party
(other than the Directors and the chief executives of the
Company) who had, or was deemed to have, interests
or short positions in the shares, underlying shares and
debentures of the Company (i) which would fall to be
disclosed to the Company and Stock Exchange under
the provisions of Divisions 2 and 3 of Part XV of the SFO;
or (ii) which were required, pursuant to section 336 of the
SFO, to be entered in the register referred to therein.
DIRECTOR』S RIGHT TO ACQUIRE
SHARES OR DEBENTURES
Save as disclosed under the heading 「DIRECTORS』
AND CHIEF EXECUTIVES』 INTERESTS AND SHORT
POSITIONS IN SHARES AND UNDERLYING SHARES」
above, at no time during the reporting period were rights
to acquire benefits by means of the acquisition of shares
in or debentures of the Company or of any other body
corporate granted to any directors or their respective
spouse or children under 18 years of age, or were any
such rights exercised by them; or was the Company, its
holding company or any of its subsidiaries a party to any
arrangements to enable the Directors, their respective
spouse or children under 18 years of age to acquire such
rights in the Company or any other body corporate as at
30 June 2020.
COMPETING INTERESTS
None of the Directors or the substantial shareholders of
the Company, or any of their respective close associates
(as defined under the GEM Listing Rules) had any interest
in a business that competes or may compete with the
business of the Group during the six months ended 30
June 2020.
SHARE OPTIONS
The Share Option Scheme adopted by the Company
on 14 September 2011 is for the primary purpose of
providing incentives to directors and eligible employees of
the Group.
除上文所披露者外，於二零二零
年六月三十日，董事概不知悉任
何其他人士（董事及本公司最高行
政人員除外）於本公司股份、相關
股份及債權證中，擁有或被視作
擁有(i)根據證券及期貨條例第XV
部第2及3分部之條文須向本公司
及聯交所披露之權益或淡倉；或
(ii)根據證券及期貨條例第336條須
記入該條所述登記冊內之權益或
淡倉。
董事收購股份或債權
證之權利
除上文「董事及最高行政人員於股
份及相關股份之權益及淡倉」一節
所披露者外，於報告期內任何時
間，概無任何董事或彼等各自之
配偶或未滿18歲之子女獲授或行
使任何可透過購買本公司或任何
其他法人團體之股份或債權證而
獲益之權利；截至二零二零年六
月三十日，本公司、其控股公司
或其任何附屬公司亦無訂立任何
安排，致使董事、彼等各自之配
偶或未滿18歲之子女獲得本公司
或任何其他法人團體之該等權利。
競爭權益
截至二零二零年六月三十日止六
個月，概無任何董事或本公司主
要股東或任何彼等各自之緊密聯
繫人（定義見
GEM上市規則）於與
本集團業務構成競爭或可能構成
競爭之業務中擁有任何權益。
購股權
於二零一一年九月十四日，本公
司採納購股權計劃，主要目的為
向本集團董事及合資格僱員提供
獎勵。
The movement of share options under the share option 於截至二零二零年六月三十日止
scheme adopted by the Company on 14 September 六個月，本公司於二零一一年九
2011 during the six months ended 30 June 2020 was as 月十四日採納之購股權計劃項下
below: 之購股權變動如下：
Movement of Share Options during the six months ended 30 June 2020
截至二零二零年六月三十日止六個月之購股權變動
Adjusted Outstanding Outstanding
exercise as at as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$) of the Share Options Share Options granted (Note) (Note) (Note) (Note) (Note) (Note)
經調整於二零一九年於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
Directors16/9/20150.45 9.00 16 September 2016 to
董事
二零一五年15 September 2017
九月十六日
(both days inclusive)
(the 「1st Period」)
二零一六年九月十六日至
二零一七年九月十五日
（包括首尾兩日）
（「第一個期間」）
16 September 2017 to
15 September 2018
(both days inclusive)
(the 「2nd Period」)
二零一七年九月十六日至
二零一八年九月十五日
（包括首尾兩日）
（「第二個期間」）
16 September 2018 to
15 September 2019
(both days inclusive)
(the 「3rd Period」)
二零一八年九月十六日至
二零一九年九月十五日
（包括首尾兩日）
（「第三個期間」）
16 September 2019 to
15 September 2020
(both days inclusive)
(the 「4th Period」)
二零一九年九月十六日至
二零二零年九月十五日
（包括首尾兩日）
（「第四個期間」）
Up to 20% (「1st Options」)57,900 NILNILNILNIL57,900
最多20%（「第一份購股權」）
無
無
無
無
Up to 20% (「2nd Options」)
(together with any 1st
Options which have not
been exercised during the
1st Period)
最多20%（「第二份購股權」）
（連同於第一個期間
尚未行使之任何
第一份購股權）
Up to 20% (「3rd Options」)
(together with any 1st and
2nd Options which have not
been exercised during the
1st Period and 2nd Period)
最多20%（「第三份購股權」）
（連同於第一個期間及
第二個期間尚未行使之任何
第一份及第二份購股權）
Up to 20% (「4th Options」)
(together with any 1st, 2nd
and 3rd Options which have
not been exercised during
the 1st Period, 2nd Period
and 3rd Period)
最多20%（「第四份購股權」）
（連同於第一個期間、
第二個期間及第三個
期間尚未行使之任何
第一份、第二份及
第三份購股權）
Movement of Share Options during the six months ended 30
截至二零二零年六月三十日止六個月之購股權變動
June 2020Adjusted
exercise
Outstanding
as at
Outstanding
as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$)
經調整
of the Share Options Share Options granted (Note)
於二零一九年
(Note) (Note) (Note) (Note) (Note)
於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
16 September 2020 to
15 September 2025
(both days inclusive)
(the 「5th Period」)
二零二零年九月十六日至
二零二五年九月十五日
（包括首尾兩日）
（「第五個期間」）
Directors9/9/20160.291 5.820 9 September 2017 to
董事
二零一六年8 September 2018
九月九日
(both days inclusive)
(the 「1st Period」)
二零一七年九月九日至
二零一八年九月八日
（包括首尾兩日）
（「第一個期間」）
9 September 2018 to
8 September 2019
(both days inclusive)
(the 「2nd Period」)
二零一八年九月九日至
二零一九年九月八日
（包括首尾兩日）
（「第二個期間」）
9 September 2019 to
8 September 2020
(both days inclusive)
(the 「3rd Period」)
二零一九年九月九日至
二零二零年九月八日
（包括首尾兩日）
（「第三個期間」）
Up to 20% (「5th Options」)
(together with any 1st, 2nd,
3rd and 4th Options which
have not been exercised
during the 1st Period,
2nd Period, 3rd Period
and 4th Period)
最多20%（「第五份購股權」）
（連同於第一個期間、
第二個期間、第三個
期間及第四個期間
尚未行使之任何第一份、
第二份、第三份及
第四份購股權）
Up to 20% (「1st Options」)46,000 NILNILNILNIL46,000
最多20%（「第一份購股權」）
無
無
無
無
Up to 20% (「2nd Options」)
(together with any 1st
Options which have not
been exercised during the
1st Period)
最多20%（「第二份購股權」）
（連同於第一個期間
尚未行使之任何
第一份購股權）
Up to 20% (「3rd Options」)
(together with any 1st and
2nd Options which have not
been exercised during the
1st Period and
2nd Period)
最多20%（「第三份購股權」）
（連同於第一個期間及
第二個期間尚未行使之
任何第一份及第二份
購股權）
Movement of Share Options during the six months ended 30 June 2020
截至二零二零年六月三十日止六個月之購股權變動
Adjusted Outstanding Outstanding
exercise as at as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$) of the Share Options Share Options granted (Note) (Note) (Note) (Note) (Note) (Note)
經調整於二零一九年於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
9 September 2020 to
8 September 2021
(both days inclusive)
(the 「4th Period」)
二零二零年九月九日至
二零二一年九月八日
（包括首尾兩日）
（「第四個期間」）
9 September 2021 to
8 September 2025
(both days inclusive)
(the 「5th Period」)
二零二一年九月九日至
二零二五年九月八日
（包括首尾兩日）
（「第五個期間」）
Up to 20% (「4th Options」)
(together with any 1st, 2nd
and 3rd Options which have
not been exercised during
the 1st Period, 2nd Period
and 3rd Period)
最多20%（「第四份購股權」）
（連同於第一個期間、
第二個期間及第三個
期間尚未行使之任何
第一份、第二份及
第三份購股權）
Up to 20% (「5th Options」)
(together with any 1st, 2nd,
3rd and 4th Options which
have not been exercised
during the 1st Period, 2nd
Period, 3rd Period and 4th
Period)
最多20%（「第五份購股權」）
（連同於第一個期間、
第二個期間、第三個
期間及第四個期間尚未
行使之任何第一份、
第二份、第三份及
第四份購股權）
Movement of Share Options during the six months ended 30
截至二零二零年六月三十日止六個月之購股權變動
June 2020Adjusted
exercise
Outstanding
as at
Outstanding
as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$)
經調整
of the Share Options Share Options granted (Note)
於二零一九年
(Note) (Note) (Note) (Note) (Note)
於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
Others16/9/20150.45 9.00 For Grantees other than new employees who have joined the 3,492,500 NILNILNIL(190,500) 3,302,000
其他人士
二零一五年Company for less than 12 months or are yet to commence 無
無
無
九月十六日
work with the Company on the relevant date of grant (as the
case may be):
就於相關授出日期之承授人（除加入本公司少於十二個月或仍未
開始於本公司任職之新僱員外）而言（視情況而定）：
1st Period1st Options
第一個期間
第一份購股權
2nd Period2nd Options (together with any
第二個期間
1st Options which have not
been exercised during the
1st Period)
第二份購股權（連同於第一個
期間尚未行使之任何
第一份購股權）
3rd Period3rd Options (together with any
第三個期間
1st and 2nd Options which
have not been exercised
during the 1st Period and
2nd Period)
第三份購股權（連同於第一個
期間及第二個期間
尚未行使之任何
第一份及第二份購股權）
4th Period4th Options (together with any
第四個期間
1st, 2nd and 3rd Options
which have not been
exercised during the 1st
Period, 2nd Period and 3rd
Period)
第四份購股權（連同於
第一個期間、第二個
期間及第三個期間尚未
行使之任何第一份、第二份
及第三份購股權）
5th Period5th Options (together with
第五個期間
any 1st, 2nd, 3rd and 4th
Options which have not
been exercised during the
1st Period, 2nd Period, 3rd
Period and 4th Period)
第五份購股權（連同於
第一個期間、第二個
期間、第三個期間及
第四個期間尚未行使之
任何第一份、第二份、
第三份及第四份購股權）
Movement of Share Options during the six months ended 30 June 2020
截至二零二零年六月三十日止六個月之購股權變動
Adjusted Outstanding Outstanding
exercise as at as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$) of the Share Options Share Options granted (Note) (Note) (Note) (Note) (Note) (Note)
經調整於二零一九年於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
For Grantees who are new employees who have joined the
Company for less than 12 months or are yet to commence
work with the Company on the relevant date of grant (as the
case may be):
就於相關授出日期之承授人（為加入本公司少於十二個月或仍未
開始於本公司任職之新僱員）而言（視情況而定）：
16 March 2017 to
15 March 2018
(both days inclusive)
(the 「Period 1」)
二零一七年三月十六日至
二零一八年三月十五日
（包括首尾兩日）
（「期間
1」）
16 March 2018 to
15 March 2019
(both days inclusive)
(the 「Period 2」)
二零一八年三月十六日至
二零一九年三月十五日
（包括首尾兩日）
（「期間
2」）
16 March 2019 to
15 March 2020
(both days inclusive)
(the 「Period 3」)
二零一九年三月十六日至
二零二零年三月十五日
（包括首尾兩日）
（「期間
3」）
16 March 2020 to 15 March
2021 (both days inclusive)
(the 「Period 4」)
二零二零年三月十六日至
二零二一年三月十五日
（包括首尾兩日）
（「期間
4」）
Up to 20% (「Options 1」)
最多20%（「購股權
1」）
Up to 20% (「Options 2」)
(together with any
Options 1 which have
not been exercised during
the Period 1)
最多20%（「購股權
2」）
（連同於期間1尚未行使
之任何購股權1）
Up to 20% (「Options 3」)
(together with any
Options 1 and 2
which have not been
exercised during the
Periods 1 and 2)
最多20%（「購股權
3」）
（連同於期間1及2尚未
行使之任何購股權1及2）
Up to 20% (「Options 4」)
(together with any
Options 1, 2 and 3
which have not been
exercised during the
Periods 1, 2 and 3)
最多20%（「購股權
4」）
（連同於期間1、2及
3尚未行使之任何
購股權1、2及3）
Movement of Share Options during the six months ended 30
截至二零二零年六月三十日止六個月之購股權變動
June 2020Adjusted
exercise
Outstanding
as at
Outstanding
as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$)
經調整
of the Share Options Share Options granted (Note)
於二零一九年
(Note) (Note) (Note) (Note) (Note)
於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
16 March 2021 to Up to 20% (together with any
15 September 2025 Options 1, 2, 3 and 4 which
(both days inclusive)have not been exercised
二零二一年三月十六日至during the Periods
二零二五年九月十五日1, 2, 3 and 4)
（包括首尾兩日）
最多20%（連同於期間1、2、3
及4尚未行使之任何購股權
1、2、3及4）
Others9/9/20160.291 5.82 For Grantees other than new employees who have joined the 5,278,200 NILNILNIL(182,100) 5,096,100
其他人士
二零一六年Company for less than 12 months or are yet to commence 無
無
無
九月九日
work with the Company on the relevant date of grant (as the
case may be):
就於相關授出日期之承授人（除加入本公司少於十二個月或仍未
開始於本公司任職之新僱員外）而言（視情況而定）：
the 1st Periodthe First Options
第一個期間
第一份購股權
the 2nd Periodthe Second Options (together
第二個期間
with any First Options which
have not been exercised
during the First Period)
第二份購股權（連同於
第一個期間尚未行使
之任何第一份購股權）
the 3rd Periodthe Third Options (together
第三個期間
with any First and Second
Options which have not
been exercised during the
First Period and Second
Period)
第三份購股權（連同於
第一個期間及第二個
期間尚未行使之任何
第一份及第二份購股權）
the 4th Periodthe Fourth Options (together
第四個期間
with any First, Second and
Third Options which have
not been exercised during
the First Period, Second
Period and Third Period)
第四份購股權（連同於
第一個期間、第二個
期間及第三個期間尚未
行使之任何第一份、
第二份及第三份購股權）
Movement of Share Options during the six months ended 30 June 2020
截至二零二零年六月三十日止六個月之購股權變動
Adjusted Outstanding Outstanding
exercise as at as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$) of the Share Options Share Options granted (Note) (Note) (Note) (Note) (Note) (Note)
經調整於二零一九年於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
the 5th Period
第五個期間
the Fifth Options (together with
any First, Second, Third and
Fourth Options which have
not been exercised during
the First Period, Second
Period, Third Period and
Fourth Period)
第五份購股權
（連同於第一個期間、
第二個期間、第三個期間
及第四個期間尚未行使
之任何第一份、第二份、
第三份及第四份購股權）
For Grantees who are new employees who have joined the
Company for less than 12 months or are yet to commence
work with the Company on the relevant date of grant (as the
case may be):
就於相關授出日期之承授人（為加入本公司少於十二個月或仍未
開始於本公司任職之新僱員）而言（視情況而定）：
9 March 2018 to
8 March 2019
(both days inclusive)
(the 「I Period」)
二零一八年三月九日至
二零一九年三月八日
（包括首尾兩日）
（「期間
I」）
9 March 2019 to
8 March 2020
(both days inclusive)
(the 「II Period」)
二零一九年三月九日至
二零二零年三月八日
（包括首尾兩日）
（「期間
II」）
9 March 2020 to
8 March 2021
(both days inclusive)
(the 「III Period」)
二零二零年三月九日至
二零二一年三月八日
（包括首尾兩日）
（「期間
III」）
Up to 20% (「Options I」)
最多20%（「購股權
I」）
Up to 20% (「Options II」)
(together with any
Options I which have
not been exercised during
the I Period)
最多20%（「購股權
II」）
（連同於期間I尚未
行使之任何購股權I）
Up to 20% (「Options III」)
(together with any
Options I and II which have
not been exercised during
the I and II Periods)
最多20%（「購股權
III」）
（連同於期間I及II尚未
行使之任何購股權I及II）
Movement of Share Options during the six months ended 30
截至二零二零年六月三十日止六個月之購股權變動
June 2020Adjusted
exercise
Outstanding
as at
Outstanding
as at
Exercise price Vesting schedule Exercisable 31 December 30 June
Eligible Date of price (Note) and exercise period portion of the 2019 Granted Exercised Reclassified Lapsed 2020
persons grant (HK$) (HK$)
經調整
of the Share Options Share Options granted (Note)
於二零一九年
(Note) (Note) (Note) (Note) (Note)
於二零二零年
行使價購股權之十二月三十一日六月三十日
行使價（附註）歸屬時間表及已授出購股權之尚未行使已授出已行使已重新分類已失效尚未行使
合資格人士授出日期（港元）（港元）可行使期間可行使部份（附註）（附註）（附註）（附註）（附註）（附註）
9 March 2021 to Up to 20% (「Options IV」)
8 March 2022 (together with any Options
(both days inclusive) I, II and III which have not
(the 「IV Period」)been exercised during
二零二一年三月九日至the I, II and III Periods)
二零二二年三月八日最多20%（「購股權
IV」）
（包括首尾兩日）（連同於期間I、II及III（「期間
IV」）
尚未行使之任何
購股權I、II及III）
9 March 2022 to Up to 20% (together with any
8 September 2025 Options I, II, III and IV which
(both days inclusive)have not been exercised
二零二二年三月九日至during the I, II, III and IV
二零二五年九月八日Periods)
（包括首尾兩日）
最多20%（連同於期間I、II、III
及IV尚未行使之任何購股權
I、II、III及IV）
Note:
By virtue of a share consolidation of the Company
whereby every 20 of then existing issued and unissued
shares of HK$0.01 each in the share capital of the
Company was consolidated into 1 consolidated share of
HK$0.20 each. The share consolidation took effect on 16
May 2019.
The number of shares and exercise price under the share
option scheme were adjusted accordingly.
COMPETING INTERESTS
None of the Directors or the substantial shareholders of
the Company, or any of their respective close associates
(as defined under the GEM Listing Rules) had any interest
in a business that competes or may compete with the
business of the Group during the six months ended 30
June 2020.
CORPORATE GOVERNANCE
PRACTICE
The Company has complied with all the code provisions
set out in the Corporate Governance Code and
Corporate Governance Report contained in Appendix
15 to the GEM Listing Rules throughout the six months
ended 30 June 2020.
附註：由於本公司進行股份合併，本
公司其時股本中每
20股每股
0.01港元的已發行及未發行股
份合併為1股每股0.20港元的合
併股份。股份合併於二零一九
年五月十六日生效。
購股權計劃項下的股份數目及
行使價亦作相應調整。
競爭權益
截至二零二零年六月三十日止六
個月期間，董事或本公司主要股
東或任何彼等各自之緊密聯繫人
（定義見
GEM上市規則）概無在與
本集團業務構成競爭或可能構成
競爭之業務中擁有任何權益。
企業管治常規
本公司於截至二零二零年六月三
十日止六個月已遵守GEM上市規
則附錄十五所載之企業管治守則
及企業管治報告之所有守則條文。
INTERESTS OF THE COMPLIANCE
ADVISER
In accordance with Rule 6A.20 of the GEM Listing Rules,
the Company has appointed Octal Capital Limited (「Octal
Capital」) as its compliance adviser, which provides
advices and guidance to the Company in respect of
compliance with the GEM Listing Rules including various
requirements relating to Directors』 duties. As notified
by Octal Capital, except for the compliance adviser
agreement entered into between the Company and
Octal Capital on 12 August 2019, neither Octal Capital
nor its directors, employees or close associates had any
interests in relation to the Company which is required to
be notified to the Group pursuant to Rule 6A.32 of the
GEM Listing Rules as at the date of this report.
AUDIT COMMITTEE
The audit committee of the Company (the 「Audit
Committee」) has three members, comprising all
independent non-executive Directors, namely Ms. Yang
Ying (the chairman of the Audit Committee), Ms. Huo
Chunyu and Dr. Fang Jun. The Company’s unaudited
condensed consolidated financial statements for the six
months ended 30 June 2020 have been reviewed by the
Audit Committee.
DISCLOSURE OF INFORMATION
OF DIRECTORS AND CHIEF
EXECUTIVES
Pursuant to Rule 17.50A(1) of the GEM Listing Rules, the
changes in information of Directors and chief executives
subsequent to the date of the 2019 Annual Report of the
Company are set out below:
Name of Directors
and chief executives Details of Changes
董事及最高行政人員姓名變動詳情
合規顧問權益
根據GEM上市規則第6A.20條，
本公司已委任八方金融有限公司
（「八方金融」）為其合規顧問，就
遵守GEM上市規則（包括有關董
事職責的各項規定）向本公司提
供建議及指引。誠如八方金融告
悉，除本公司與八方金融訂立日
期為二零一九年八月十二日的合
規顧問協議外，八方金融、其董
事、僱員或緊密聯繫人概無擁有
任何與本公司有關而須於本報告
日期根據GEM上市規則第6A.32
條知會本集團的任何權益。
審核委員會
本公司之審核委員會（「審核委員
會」）有三位成員，包括所有獨立
非執行董事，即楊瀅女士（審核委
員會主席）、霍春玉女士及方俊博
士。審核委員會已審閱本公司截
至二零二零年六月三十日止六個
月之未經審核簡明綜合財務報表。
有關董事及最高行政
人員之披露資料
根據GEM上市規則第17.50A(1)
條，於本公司二零一九年年報日
期後之董事及最高行政人員的資
料變動載列如下：
Mr. Wang Xuejun
王學軍先生
Mr, Wang Chuang
王闖先生
Mr. Wang Xuejun resigned from his position as executive
Director and chief executive officer of the Company with
effect from 9 July 2020.
王學軍先生自二零二零年七月九日起辭任本公司執行董事及
行政總裁。
Mr, Wang Chuang, an executive Director and Chairman, was
appointed as chief executive officer of the Company with
effect from 9 July 2020.
執行董事及主席王闖先生自二零二零年七月九日起獲委任為
本公司行政總裁。
SECURITIES DEALING CODE
The Company has adopted the code of conduct for
dealing in securities by the Directors as set out in
the GEM Listing Rules 5.48 to 5.67 as its own code
for transactions in securities of the Company by the
Directors (the 「Required Standard of Dealings」). Having
made specific enquiry of all Directors, all Directors have
confirmed that they have fully complied with the Required
Standard of Dealings throughout the six months ended
30 June 2020.
PURCHASE, SALE OR
REDEMPTION OF SECURITIES
During the six months ended 30 June 2020 neither
the Company nor any of its subsidiaries purchased,
redeemed or sold any of the Company’s listed securities.
By Order of the Board of
China Regenerative Medicine International Limited
Mr Wang Chuang
Chairman, Chief Executive Officer and Executive Director
Hong Kong, 31 July 2020
As at the date of this report, the executive Directors are
Mr. Wang Chuang (Chairman and Chief Executive Officer)
and Mr. Qiu Bin; the non-executive Directors are Mr. Wu
Weiliang and Mr. Tsang Ho Yin; and the independent
non-executive Directors are Dr. Fang Jun, Ms. Huo
Chunyu and Ms. Yang Ying.
This report will remain on the 「Latest Company
Information」 page of the GEM website at www.hkgem.com
for at least seven days from the date of the publication
and will be published on the website of the Company at
www.crmi.hk.
證券交易守則
本公司已採納GEM上市規則第
5.48至5.67條所載董事進行證券
交易之操作守則作為其自身董事
進行本公司證券交易之守則（「規
定交易標準」）。本公司經向全體
董事作出特別垂詢後，全體董事
已確認彼等於截至二零二零年六
月三十日止六個月已全面遵守規
定交易標準。
購買、出售或贖回
證券
於截至二零二零年六月三十日止
六個月，本公司及其任何附屬公
司概無購買、贖回或出售任何本
公司上市證券。
承董事會命
中國再生醫學國際有限公司
主席、行政總裁兼執行董事
王闖先生
香港，二零二零年七月三十一日
於本報告日期，執行董事為王闖
先生（主席兼行政總裁）及邱斌先
生；非執行董事為吳偉良先生及
曾浩賢先生；及獨立非執行董事
為方俊博士、霍春玉女士及楊瀅
女士。
本報告將由刊發日期起計於GEM
網站
www.hkgem.com之「最新公司
公告」一頁至少保留七日及於本公
司之網站www.crmi.hk內登載。
中財網